Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileAnthony V. D'Amico, M.D., Ph.D.

TitleProfessor of Radiation Oncology
InstitutionBrigham and Women's Hospital
DepartmentRadiation Oncology
AddressBrigham and Women's Hospital
Radiation Oncology
75 Francis St
Boston MA 02115
Phone617/732-7936
Fax617/732-7347
vCardDownload vCard (login for email)
Other Positions
TitleAdvisory Dean, Oliver Wendell Holmes Society
InstitutionHarvard Medical School
DepartmentPME


Collapse Mentoring 
Collapse completed student projects
International Clinical Elective - MICEFA French International Clinical Elective at Université Pierre et Marie Curie, spring 2013
International, 03/04/13 - 04/12/13
International Clinical Elective - MICEFA Exchange, spring 2013 at Hôpital Antoine-Béclère
International, 03/11/13 - 04/05/13
H2O2, Autophagy and the mTOR Pathway: is there a Link?
Summer, 06/12/13 - 08/02/13
Can MRI Staging of the Prostate Identify High-Risk and Low-Risk Patients for PSA Failure After Radiation for Prostate Cancer?
Full Time/Year Long, 07/01/02 - 06/30/03

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Royce TJ, Chen MH, D'Amico AV. Validity of Surrogate End Points for Prostate Cancer-Reply. JAMA Oncol. 2017 Aug 31. PMID: 28859194.
    View in: PubMed
  2. D'Amico AV. Reply to D.E. Spratt. J Clin Oncol. 2017 Sep 01; 35(25):2979. PMID: 28682687.
    View in: PubMed
  3. Royce TJ, Chen MH, Wu J, Loffredo M, Renshaw AA, Kantoff PW, D'Amico AV. Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 May 01; 3(5):652-658. PMID: 28097317.
    View in: PubMed
  4. D'Amico AV. Decipher Postprostatectomy: Is It Ready for Clinical Use? J Clin Oncol. 2017 Jun 20; 35(18):1976-1977. PMID: 28358652.
    View in: PubMed
  5. D'Amico AV. Active Surveillance Versus Treatment of Prostate Cancer: Should Metastasis Be the Primary End Point? J Clin Oncol. 2017 May 20; 35(15):1638-1640. PMID: 28240975.
    View in: PubMed
  6. McLaughlin PW, Liss AL, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, Movsas B, Prestidge BR, Showalter TN, Taira AV, Vapiwala N, Davis BJ. ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer. Am J Clin Oncol. 2017 Feb; 40(1):1-10. PMID: 28059930.
    View in: PubMed
  7. Patel SA, Chen MH, Loffredo M, Renshaw A, Kantoff PW, D'Amico AV. The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 Jun; 20(2):234-240. PMID: 28117382.
    View in: PubMed
  8. D'Amico AV. 10-Year Outcomes in Localized Prostate Cancer. N Engl J Med. 2017 01 12; 376(2):181. PMID: 28079333.
    View in: PubMed
  9. Lester-Coll NH, Johnson S, Magnuson WJ, Goldhaber SZ, Sher DJ, D'Amico AV, Yu JB. Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. J Natl Cancer Inst. 2017 06; 109(6). PMID: 28040795.
    View in: PubMed
  10. Mouw KW, D'Amico AV. Post-Prostatectomy Radiation Therapy: Balancing Disease Control and Functional Outcomes. J Urol. 2017 Mar; 197(3 Pt 1):541-542. PMID: 27993664.
    View in: PubMed
  11. Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N. ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy. 2017 Mar - Apr; 16(2):266-276. PMID: 27964905.
    View in: PubMed
  12. Sanford NN, Chen MH, Loffredo M, Renshaw A, Kantoff PW, D'Amico AV. Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death. Prostate Cancer Prostatic Dis. 2017 Mar; 20(1):79-84. PMID: 27824043.
    View in: PubMed
  13. Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ. ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Adv Radiat Oncol. 2017 Jan-Mar; 2(1):62-84. PMID: 28740916.
    View in: PubMed
  14. D'Amico AV. Treatment or Monitoring for Early Prostate Cancer. N Engl J Med. 2016 10 13; 375(15):1482-1483. PMID: 27627134.
    View in: PubMed
  15. Giacalone NJ, Wu J, Chen MH, Renshaw A, Loffredo M, Kantoff PW, D'Amico AV. Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial. J Clin Oncol. 2016 Sep 06. PMID: 27601545.
    View in: PubMed
  16. Rose BS, Chen MH, Wu J, Braccioforte MH, Moran BJ, Doseretz DE, Katin MJ, Ross RH, Salenius SA, D'Amico AV. Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality. Int J Radiat Oncol Biol Phys. 2016 Nov 15; 96(4):778-784. PMID: 27788950.
    View in: PubMed
  17. Kovtun KA, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer. Cancer. 2016 Dec 01; 122(23):3608-3614. PMID: 27490845.
    View in: PubMed
  18. Martin NE, Chen MH, Zhang D, Richie JP, D'Amico AV. Unfavorable Intermediate-Risk Prostate Cancer and the Odds of Upgrading to Gleason 8 or Higher at Prostatectomy. Clin Genitourin Cancer. 2017 Apr; 15(2):237-241. PMID: 27426058.
    View in: PubMed
  19. Belz J, Kumar R, Makrigiorgos G, D'Amico A, Nguyen P, Cormack R, Sridhar S. WE-FG-BRA-02: Docetaxel Eluting Brachytherapy Spacers for Local Chemo-Radiation Therapy in Prostate Cancer. Med Phys. 2016 Jun; 43(6):3823. PMID: 28046887.
    View in: PubMed
  20. Keane FK, D'Amico AV. Androgen deprivation therapy use and risk of death in men treated with high-dose radiation for intermediate-risk prostate cancer. Cancer. 2016 08 01; 122(15):2296-8. PMID: 27191800.
    View in: PubMed
  21. D'Amico AV. Can short-term hormone therapy for rising PSA prolong survival? Lancet Oncol. 2016 Jun; 17(6):687-688. PMID: 27160478.
    View in: PubMed
  22. D'Amico A, Matthews T, Wood R, Paolone V. The Effect Of Foam Rolling On Recovery Between Two 800-m Runs: 1298 Board #1 June 2, 8: 00 AM - 10: 00 AM. Med Sci Sports Exerc. 2016 May; 48(5 Suppl 1):337-8. PMID: 27584337.
    View in: PubMed
  23. Bonanni L, Di Giacomo R, D'Amico A, Frazzini V, Franciotti R, Manzoli L, Thomas A, Onofrj M. Akinetic crisis in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2016 Oct; 87(10):1123-6. PMID: 27068351.
    View in: PubMed
  24. Huynh MA, Chen MH, Wu J, Braccioforte MH, Moran BJ, D'Amico AV. Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy Alone. Int J Radiat Oncol Biol Phys. 2016 Jul 15; 95(4):1158-67. PMID: 27209511.
    View in: PubMed
  25. D'Amico AV, Chen MH, Kantoff PW. Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer--Reply. JAMA. 2016 Mar 08; 315(10):1055-6. PMID: 26954420.
    View in: PubMed
  26. Mihalcik SA, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOT. Eur Urol Focus. 2016 Mar 03. PMID: 28753752.
    View in: PubMed
  27. D'Amico AV. Pelvis Plus Prostate Radiation Therapy and the Risk of Death in Men With Newly Diagnosed Node-Positive Prostate Cancer. JAMA Oncol. 2016 Mar; 2(3):357-8. PMID: 26605852.
    View in: PubMed
  28. D'Amico AV. Reply to M.C. Scholz et al. J Clin Oncol. 2016 Apr 10; 34(11):1284. PMID: 26884570.
    View in: PubMed
  29. Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D'Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I. Screening for familial and hereditary prostate cancer. Int J Cancer. 2016 Jun 01; 138(11):2579-91. PMID: 26638190.
    View in: PubMed
  30. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016 Jan; 14(1):19-30. PMID: 26733552.
    View in: PubMed
  31. Huynh MA, Chen MH, Wu J, Braccioforte MH, Moran BJ, D'Amico AV. Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death. Eur Urol. 2016 Jun; 69(6):976-9. PMID: 26388503.
    View in: PubMed
  32. D'Amico AV. Is Gleason Grade 5 Prostate Cancer Resistant to Conventional Androgen Deprivation Therapy? Eur Urol. 2016 May; 69(5):761-3. PMID: 26364550.
    View in: PubMed
  33. Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy. Brachytherapy. 2015 Nov-Dec; 14(6):781-7. PMID: 26361718.
    View in: PubMed
  34. D'Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW. Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA. 2015 Sep 22-29; 314(12):1291-3. PMID: 26393854.
    View in: PubMed
  35. D'Amico AV. Personalizing the Use of Active Surveillance As an Initial Approach for Men With Newly Diagnosed Prostate Cancer. J Clin Oncol. 2015 Oct 20; 33(30):3365-6. PMID: 26324374.
    View in: PubMed
  36. Ross AE, D'Amico AV, Freedland SJ. Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis. 2016 Mar; 19(1):1-6. PMID: 26123120.
    View in: PubMed
  37. Ennis KY, Chen MH, Smith GC, D'Amico AV, Zhang Y, Quinn SA, Ryemon SN, Goltz D, Harrison LB, Ennis RD. The Impact of Economic Recession on the Incidence and Treatment of Cancer. J Cancer. 2015; 6(8):727-33. PMID: 26185534; PMCID: PMC4504108.
  38. Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer. JAMA Oncol. 2015 Jun; 1(3):334-40. PMID: 26181182.
    View in: PubMed
  39. Braunstein LZ, Chen MH, Dosoretz DE, Salenius SA, Katin MJ, Nanda A, D'Amico AV. Whole Pelvis Versus Prostate-Only Radiotherapy With or Without Short-Course Androgen Deprivation Therapy and Mortality Risk. Clin Genitourin Cancer. 2015 Dec; 13(6):555-61. PMID: 26003267.
    View in: PubMed
  40. Keane FK, Chen MH, Zhang D, Moran BJ, Braccioforte MH, D'Amico AV. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease. Cancer. 2015 Aug 15; 121(16):2713-9. PMID: 25925789.
    View in: PubMed
  41. Mahal BA, Chen MH, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV, Nguyen PL. High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? Ann Oncol. 2015 Jul; 26(7):1390-5. PMID: 25926039; PMCID: PMC4478973 [Available on 07/01/16].
  42. Lago-Hernandez CA, Feldman H, O'Donnell E, Mahal BA, Perez V, Howard S, Rosenthal M, Cheng SC, Nguyen PL, Beard C, D'Amico AV, Sweeney CJ. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Ann Oncol. 2015 Jul; 26(7):1396-401. PMID: 25888612; PMCID: PMC4553701 [Available on 07/01/16].
  43. Zakeri K, Rose BS, D'Amico AV, Jeong JH, Mell LK. Competing events and costs of clinical trials: Analysis of a randomized trial in prostate cancer. Radiother Oncol. 2015 Apr; 115(1):114-9. PMID: 25857696.
    View in: PubMed
  44. Sammon JD, Abdollah F, D'Amico A, Gettman M, Haese A, Suardi N, Vickers A, Trinh QD. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol. 2015 Nov; 68(5):756-65. PMID: 25819724; PMCID: PMC4583348.
  45. Chandra RA, Chen MH, Zhang D, Loffredo M, D'Amico AV. Age, Comorbidity, and the Risk of Prostate Cancer-Specific Mortality in Men With Biopsy Gleason Score 4+3: Implications on Patient Selection for Multiparametric MRI. Clin Genitourin Cancer. 2015 Aug; 13(4):400-5. PMID: 25862319.
    View in: PubMed
  46. Cheney MD, Zhang D, Chen MH, Loffredo MJ, Richie JP, D'Amico AV. Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy. Clin Genitourin Cancer. 2015 Aug; 13(4):338-43. PMID: 25862320.
    View in: PubMed
  47. Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16. PMID: 25644324.
    View in: PubMed
  48. Taurisano R, D'Amico A, Colafati GS, Pichiecchio A, Catteruccia M, Bertini E, Dionisi-Vici C, Deodato F. Long-Term Follow-Up of Two Siblings with a Non-Classic Infantile Variant Form of Pompe Disease. J Neuromuscul Dis. 2015; 2(s1):S70-S71. PMID: 27858657.
    View in: PubMed
  49. Nguyen PL, D'Amico AV. Toward personalizing the use of androgen deprivation therapy to maximize benefit and minimize harm. Eur Urol. 2015 Sep; 68(3):397-8. PMID: 25542627.
    View in: PubMed
  50. D'Amico AV. Personalizing the duration of androgen-deprivation therapy use in the management of intermediate-risk prostate cancer. J Clin Oncol. 2015 Feb 01; 33(4):301-3. PMID: 25534385.
    View in: PubMed
  51. Gustafson GS, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Hsu IC, Lloyd S, Mclaughlin PW, Merrick GS, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ. ACR appropriateness Criteria® Postradical prostatectomy irradiation in prostate cancer. Oncology (Williston Park). 2014 Dec; 28(12):1125-30, 1132-6. PMID: 25510812.
    View in: PubMed
  52. Mahal BA, Inverso G, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hoffman KE, Hu JC, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Incidence and determinants of 1-month mortality after cancer-directed surgery. Ann Oncol. 2015 Feb; 26(2):399-406. PMID: 25430935.
    View in: PubMed
  53. Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D'Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015 Sep; 116(3):358-65. PMID: 25124891.
    View in: PubMed
  54. Mahal BA, Chen MH, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV, Nguyen PL. The association between race and treatment regret among men with recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2015 Mar; 18(1):38-42. PMID: 25348256.
    View in: PubMed
  55. Inverso G, Aizer AA, Ziehr DR, Hyatt A, Choueiri TK, Hoffman KE, Hu JC, Beard C, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Incidence and determinants of 1-month mortality after cancer-directed surgery. J Clin Oncol. 2014 Oct 20; 32(30_suppl):282. PMID: 28141239.
    View in: PubMed
  56. Ziehr DR, Mahal BA, Aizer AA, Hyatt AS, Beard CJ, D Amico AV, Choueiri TK, Elfiky A, Lathan CS, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015 Jan; 33(1):18.e7-18.e13. PMID: 25306287.
    View in: PubMed
  57. Koontz BF, Bossi A, Cozzarini C, Wiegel T, D'Amico A. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol. 2015 Oct; 68(4):683-91. PMID: 25171903.
    View in: PubMed
  58. Martin NE, D'Amico AV. Progress and controversies: Radiation therapy for prostate cancer. CA Cancer J Clin. 2014 Nov-Dec; 64(6):389-407. PMID: 25234700.
    View in: PubMed
  59. Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, Blute M, Catto J, Chen RC, D'Amico AV, Feick G, Fitzpatrick JM, Frank SJ, Froehner M, Frydenberg M, Glaser A, Graefen M, Hamstra D, Kibel A, Mendenhall N, Moretti K, Ramon J, Roos I, Sandler H, Sullivan FJ, Swanson D, Tewari A, Vickers A, Wiegel T, Huland H. Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol. 2015 Mar; 67(3):460-7. PMID: 25234359.
    View in: PubMed
  60. D'Amico AV. Reply to K. Quan et Al, S.P. Collins et al, C.R. King et al, s. Arcangeli et al, d.B. Fuller, and D. Vordermark. J Clin Oncol. 2014 Oct 20; 32(30):3457. PMID: 25185103.
    View in: PubMed
  61. Pashtan I, Chen MH, D'Amico AV. The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml. Cancer Epidemiol. 2014 Oct; 38(5):613-8. PMID: 25164550.
    View in: PubMed
  62. Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015 May; 67(5):825-36. PMID: 25097095.
    View in: PubMed
  63. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Lago-Hernandez C, Chen YW, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Trinh QD, Nguyen PL. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):273-9. PMID: 24980272.
    View in: PubMed
  64. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014 Aug; 84(2):386-92. PMID: 24975710.
    View in: PubMed
  65. Nguyen PL, Aizer A, Assimos DG, D'Amico AV, Frank SJ, Gottschalk AR, Gustafson GS, Hsu IC, McLaughlin PW, Merrick G, Rosenthal SA, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ. ACR Appropriateness Criteria® Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88. PMID: 25180754.
    View in: PubMed
  66. Mahal BA, Ziehr DR, Hyatt AS, Neubauer-Sugar EH, O'Farrell DA, O'Leary MP, Steele GS, Niedermayr TR, Beard CJ, Martin NE, Orio PF, D'Amico AV, Devlin PM, Nguyen PL. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. Brachytherapy. 2014 Sep-Oct; 13(5):442-9. PMID: 24880584.
    View in: PubMed
  67. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. Response to Drs Rogers, Hayes, and Demanes. Brachytherapy. 2014 Sep-Oct; 13(5):523-5. PMID: 24880587.
    View in: PubMed
  68. Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL. Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. J Geriatr Oncol. 2014 Oct 01; 5(4):352-8. PMID: 24862107.
    View in: PubMed
  69. Talcott JA, Manola J, Chen RC, Clark JA, Kaplan I, D'Amico AV, Zietman AL. Using patient-reported outcomes to assess and improve prostate cancer brachytherapy. BJU Int. 2014 Oct; 114(4):511-6. PMID: 24112602.
    View in: PubMed
  70. Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Lathan C, Kim SP, Trinh QD, Nguyen PL. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014 Nov; 32(8):1285-91. PMID: 24846344.
    View in: PubMed
  71. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):e189-95. PMID: 24861952.
    View in: PubMed
  72. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May; 12(5):686-718. PMID: 24812137.
    View in: PubMed
  73. Braunstein LZ, Chen MH, Loffredo M, Kantoff PW, D'Amico AV. Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer. Prostate Cancer. 2014; 2014:230812. PMID: 24864213; PMCID: PMC4016923.
  74. Tanguturi SK, Chen MH, Loffredo M, Richie JP, D'Amico AV. Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort. Prostate Cancer. 2014; 2014:395078. PMID: 24829803; PMCID: PMC4009223.
  75. Asimakopoulos AD, Del Fabbro D, Miano R, Santonico M, Capuano R, Pennazza G, D'Amico A, Finazzi-Agrò E. Prostate cancer diagnosis through electronic nose in the urine headspace setting: a pilot study. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):206-11. PMID: 24686772.
    View in: PubMed
  76. Rose BS, Chen MH, Zhang D, Hirsch MS, Richie JP, Chang SL, Hegde JV, Loffredo MJ, D'Amico AV. Maximum tumor diameter and the risk of prostate-specific antigen recurrence after radical prostatectomy. Clin Genitourin Cancer. 2014 Oct; 12(5):e173-9. PMID: 24787967.
    View in: PubMed
  77. D'Amico AV. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: less cost at the expense of more genitourinary toxicity is a concerning but testable hypothesis. J Clin Oncol. 2014 Apr 20; 32(12):1183-5. PMID: 24616317.
    View in: PubMed
  78. Keane FK, Chen MH, Zhang D, Loffredo MJ, Kantoff PW, Renshaw AA, D'Amico AV. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer. 2014 Jun 15; 120(12):1787-93. PMID: 24604289.
    View in: PubMed
  79. Phillips JG, Aizer AA, Chen MH, Zhang D, Hirsch MS, Richie JP, Tempany CM, Williams S, Hegde JV, Loffredo MJ, D'Amico AV. The effect of differing Gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):e181-7. PMID: 24721618; PMCID: PMC4153802.
  80. Martin NE, Chen MH, Beard CJ, Nguyen PL, Loffredo MJ, Renshaw AA, Kantoff PW, D'Amico AV. Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. Prostate Cancer. 2014; 2014:912943. PMID: 24701353; PMCID: PMC3950926.
  81. Chandra RA, Chen MH, Zhang D, Loffredo M, D'Amico AV. Evidence suggesting that obesity prevention measures may improve prostate cancer outcomes using data from a prospective randomized trial. Prostate Cancer. 2014; 2014:478983. PMID: 24693436; PMCID: PMC3945618.
  82. Cheney MD, Chen MH, Zhang D, Phillips JG, Loffredo MJ, D'Amico AV. Greatest percentage of involved core length and the risk of death from prostate cancer in men with highest Gleason score = 7. Clin Genitourin Cancer. 2014 Aug; 12(4):234-40. PMID: 24594503.
    View in: PubMed
  83. Mirabeau-Beale K, Chen MH, D'Amico AV. Prior-cancer diagnosis in men with nonmetastatic prostate cancer and the risk of prostate-cancer-specific and all-cause mortality. ISRN Oncol. 2014; 2014:736163. PMID: 24634786; PMCID: PMC3929377.
  84. Mazzone E, De Sanctis R, Fanelli L, Bianco F, Main M, van den Hauwe M, Ash M, de Vries R, Fagoaga Mata J, Schaefer K, D'Amico A, Colia G, Palermo C, Scoto M, Mayhew A, Eagle M, Servais L, Vigo M, Febrer A, Korinthenberg R, Jeukens M, de Viesser M, Totoescu A, Voit T, Bushby K, Muntoni F, Goemans N, Bertini E, Pane M, Mercuri E. Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients. Neuromuscul Disord. 2014 Apr; 24(4):347-52. PMID: 24491485.
    View in: PubMed
  85. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31. PMID: 24368283.
    View in: PubMed
  86. D'Amico AV. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. J Clin Oncol. 2014 Feb 01; 32(4):362-4. PMID: 24344221.
    View in: PubMed
  87. Caselli C, D'Amico A, Ragusa R, Caruso R, Prescimone T, Cabiati M, Nonini S, Marraccini P, Del Ry S, Trivella MG, Parodi O, Giannessi D. IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators? Mediators Inflamm. 2013; 2013:498703. PMID: 24385685; PMCID: PMC3872445.
  88. Tseng YD, Paciorek AT, Martin NE, D'Amico AV, Cooperberg MR, Nguyen PL. Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer. 2014 Mar 15; 120(6):824-32. PMID: 24301555.
    View in: PubMed
  89. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M. Prostate cancer, version 1.2014. J Natl Compr Canc Netw. 2013 Dec 01; 11(12):1471-9. PMID: 24335682.
    View in: PubMed
  90. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72. PMID: 24225970.
    View in: PubMed
  91. Nanda A, D'Amico AV. In reply to Froehner et al. Int J Radiat Oncol Biol Phys. 2013 Nov 01; 87(3):431-2. PMID: 24074910.
    View in: PubMed
  92. Aizer AA, D'Amico AV. Should all colorectal cancer patients over age 60 be screened for prostate cancer? Oncology (Williston Park). 2013 Oct; 27(10):1032-8. PMID: 24367864.
    View in: PubMed
  93. Kovtun KA, Wolfsberger L, Niedermayr T, Sugar EN, Graham PL, Murciano-Goroff Y, Beard C, D'Amico AV, Martin NE, Orio PF, Nguyen PL. Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: implications for the use of newer isotopes. Brachytherapy. 2014 Mar-Apr; 13(2):152-6. PMID: 23911279.
    View in: PubMed
  94. Moul JW, Walsh PC, Rendell MS, Lynch HT, Leslie SW, Kosoko-Lasaki O, Fitzgibbons WP, Powell I, D'Amico AV, Catalona WJ. Re: Early detection of prostate cancer: AUA guideline: H. B. Carter, P. C. Albertsen, M. J. Barry, R. Etzioni, S. J. Freedland, K. L. Greene, L. Holmberg, P. Kantoff, B. R. Konety, M. H. Murad, D. F. Penson and A. L. Zietman J Urol 2013; 190: 419-426. J Urol. 2013 Sep; 190(3):1134-7. PMID: 23871525.
    View in: PubMed
  95. D'Amico AV. Prostate cancer: where we have been, where we are, and where we are going. Semin Radiat Oncol. 2013 Jul; 23(3):155-6. PMID: 23763880.
    View in: PubMed
  96. Mazzone E, Bianco F, Main M, van den Hauwe M, Ash M, de Vries R, Fagoaga Mata J, Stein S, De Sanctis R, D'Amico A, Palermo C, Fanelli L, Scoto MC, Mayhew A, Eagle M, Vigo M, Febrer A, Korinthenberg R, de Visser M, Bushby K, Muntoni F, Goemans N, Sormani MP, Bertini E, Pane M, Mercuri E. Six minute walk test in type III spinal muscular atrophy: a 12month longitudinal study. Neuromuscul Disord. 2013 Aug; 23(8):624-8. PMID: 23809874.
    View in: PubMed
  97. Kim MB, Chen MH, de Castro M, Loffredo M, Kantoff PW, D'Amico AV. Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial. Cancer. 2013 Sep 15; 119(18):3280-6. PMID: 23798006.
    View in: PubMed
  98. D'Amico AV. Adjuvant versus salvage post-prostatectomy radiation therapy: a critical review of the evidence. J Urol. 2013 Aug; 190(2):450-1. PMID: 23688645.
    View in: PubMed
  99. Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, Schlomm T, Freedland SJ. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013 Dec; 64(6):905-15. PMID: 23721958.
    View in: PubMed
  100. Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy. 2013 Sep-Oct; 12(5):415-21. PMID: 23651926.
    View in: PubMed
  101. D'Amico AV. Personalizing the management of men with intermediate-risk prostate cancer. Eur Urol. 2013 Dec; 64(6):903-4. PMID: 23545122.
    View in: PubMed
  102. Aizer AA, Chen MH, Hattangadi J, D'Amico AV. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int. 2014 Jan; 113(1):43-50. PMID: 23473327.
    View in: PubMed
  103. Pane M, Messina S, Bruno C, D'Amico A, Villanova M, Brancalion B, Sivo S, Bianco F, Striano P, Battaglia D, Lettori D, Vita GL, Bertini E, Gualandi F, Ricotti V, Ferlini A, Mercuri E. Duchenne muscular dystrophy and epilepsy. Neuromuscul Disord. 2013 Apr; 23(4):313-5. PMID: 23465656.
    View in: PubMed
  104. Penzkofer T, Agrawal N, Kapur T, Fedorov A, Cormack RA, D'Amico AV, Tempany CM, Nguyen PL. Location of local recurrence after MRI-guided partial prostate brachytherapy targeting only the peripheral zone: Implications for focal therapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):149. PMID: 28136859.
    View in: PubMed
  105. Wolfsberger LD, Niedermayr T, Neubauer E, Murciano-Goroff YR, Beard C, D'Amico AV, Martin NE, Orio PF, Nguyen PL. Dosimetic quality and evolution of edema after prostate brachytherapy for small prostates: Implications for the use of newer isotopes. J Clin Oncol. 2013 Feb 20; 31(6_suppl):232. PMID: 28136851.
    View in: PubMed
  106. Chen MH, Moran BJ, Braccioforte MH, D'Amico AV. Intermediate versus short-course hormone therapy and mortality in men with high-risk prostate cancer treated with radiation therapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):83. PMID: 28137130.
    View in: PubMed
  107. Chen MH, D'Amico AV. Prior cancer diagnosis in men with nonmetastatic prostate cancer and the risk of prostate cancer specific and all-cause mortality. J Clin Oncol. 2013 Feb 20; 31(6_suppl):70. PMID: 28137083.
    View in: PubMed
  108. Paly JJ, Zietman AL, Nguyen PL, Beard C, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55. PMID: 28137047.
    View in: PubMed
  109. Chen MH, Beard C, Nguyen PL, Loffredo M, Renshaw AA, Kantoff PW, D'Amico AV. Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):82. PMID: 28137129.
    View in: PubMed
  110. Lester-Coll NH, Goldhaber SZ, Sher DJ, D'Amico AV. Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis. Cancer. 2013 May 15; 119(10):1808-15. PMID: 23400678.
    View in: PubMed
  111. Nanda A, Chen MH, Moran BJ, Braccioforte MH, D'Amico AV. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):e209-15. PMID: 23332383.
    View in: PubMed
  112. Parekh A, Chen MH, Hoffman KE, Choueiri TK, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, Graham PL, D'Amico AV, Nguyen PL. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology. 2013 Jan; 81(1):130-4. PMID: 23273077.
    View in: PubMed
  113. Zakeri K, Rose BS, Gulaya S, D'Amico AV, Mell LK. Competing event risk stratification may improve the design and efficiency of clinical trials: secondary analysis of SWOG 8794. Contemp Clin Trials. 2013 Jan; 34(1):74-9. PMID: 23063467; PMCID: PMC3525784.
  114. Hegde JV, Chen MH, Mulkern RV, Fennessy FM, D'Amico AV, Tempany CM. Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):e101-7. PMID: 23040223; PMCID: PMC3545042.
  115. Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM). BJU Int. 2012 Oct; 110(7):973-9. PMID: 22954029.
    View in: PubMed
  116. Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease. Eur Urol. 2014 Jan; 65(1):177-85. PMID: 22981136.
    View in: PubMed
  117. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Sep; 10(9):1081-7. PMID: 22956807.
    View in: PubMed
  118. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012 Oct 01; 30(28):3540-4. PMID: 22927523; PMCID: PMC3454771.
  119. D'Amico AV, Smith MR. Clinical decisions. Screening for prostate cancer. N Engl J Med. 2012 Aug 16; 367(7):e11. PMID: 22894598; PMCID: PMC3703939.
  120. Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol. 2012 Oct; 188(4):1151-6. PMID: 22901567; PMCID: PMC3744091.
  121. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6. PMID: 22851571.
    View in: PubMed
  122. Catalona WJ, D'Amico AV, Fitzgibbons WF, Kosoko-Lasaki O, Leslie SW, Lynch HT, Moul JW, Rendell MS, Walsh PC. What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med. 2012 Jul 17; 157(2):137-8. PMID: 22801676.
    View in: PubMed
  123. Hattangadi JA, Chen MH, D'Amico AV. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death. BJU Int. 2012 Dec; 110(11):1636-41. PMID: 22757982.
    View in: PubMed
  124. Pane M, Messina S, Vasco G, Foley AR, Morandi L, Pegoraro E, Mongini T, D'Amico A, Bianco F, Lombardo ME, Scalise R, Bruno C, Berardinelli A, Pini A, Moroni I, Mora M, Toscano A, Moggio M, Comi G, Santorelli FM, Bertini E, Muntoni F, Mercuri E. Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency. Neuromuscul Disord. 2012 Aug; 22(8):685-9. PMID: 22727687; PMCID: PMC3476532.
  125. D'Amico AV. Prostate-cancer mortality after PSA screening. N Engl J Med. 2012 Jun 07; 366(23):2229; author reply 2230-1. PMID: 22670915.
    View in: PubMed
  126. Martin NE, Chen MH, Nguyen PL, Beard CJ, Loffredo MJ, Kantoff PW, D'Amico AV. Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. BJU Int. 2012 Nov; 110(9):1252-6. PMID: 22564379.
    View in: PubMed
  127. Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. BJU Int. 2012 Oct; 110(8):1116-21. PMID: 22540922.
    View in: PubMed
  128. Chen RC, Zhang Y, Chen MH, McMahon E, Loffredo M, McPherson CP, Nguyen AU, Nguyen PL, D'Amico AV. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial. BJU Int. 2012 Dec; 110(11):1690-5. PMID: 22502770.
    View in: PubMed
  129. Tseng YD, Chen MH, Beard CJ, Martin NE, Orio PF, Loffredo M, Renshaw AA, Choueiri TK, Hu JC, Kantoff PW, D'Amico AV, Nguyen PL. Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. J Urol. 2012 Jun; 187(6):2068-73. PMID: 22498212.
    View in: PubMed
  130. Ng SK, Zygmanski P, Lyatskaya Y, D'Amico AV, Cormack RA. Localization of a portion of an endorectal balloon for prostate image-guided radiation therapy using cone-beam tomosynthesis: a feasibility study. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e257-64. PMID: 22401925.
    View in: PubMed
  131. Hattangadi JA, Chen MH, Sun L, D'Amico AV. Early detection of high-grade prostate cancer using digital rectal examination in men with a normal PSA and risk of death. J Clin Oncol. 2012 Feb 10; 30(5_suppl):147. PMID: 28143304.
    View in: PubMed
  132. Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard C, Hurwitz MD, Suh WW, D'Amico AV. Long-term results of MRI-guided partial prostate brachytherapy for favorable-risk prostate cancer: Implications for focal therapy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):114. PMID: 28143026.
    View in: PubMed
  133. Aizer A, Paly JJ, Zietman AL, D'Amico AV, Nguyen PL, Beard C, Rao SK, Kaplan ID, Hirsch MS, Wu CL, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):131. PMID: 28143227.
    View in: PubMed
  134. Parekh A, Chen MH, Hoffman KE, Choueiri TK, Hu JC, Bennett CL, Kattan MW, Sartor AO, Stein K, D'Amico AV, Nguyen PL. Incidence of reduced penis size among men with recurrent prostate cancer previously treated with surgery, radiation plus androgen deprivation, or radiation alone. J Clin Oncol. 2012 Feb 10; 30(5_suppl):38. PMID: 28142900.
    View in: PubMed
  135. Wattson DA, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Robertson CN, Polascik TJ, Braccioforte MH, Salenius SA, D'Amico AV. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):e773-9. PMID: 22300573.
    View in: PubMed
  136. Santonico M, Lucantoni G, Pennazza G, Capuano R, Galluccio G, Roscioni C, La Delfa G, Consoli D, Martinelli E, Paolesse R, Di Natale C, D'Amico A. In situ detection of lung cancer volatile fingerprints using bronchoscopic air-sampling. Lung Cancer. 2012 Jul; 77(1):46-50. PMID: 22264635.
    View in: PubMed
  137. Rosenberg JE, Chen MH, Nguyen PL, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer. Clin Genitourin Cancer. 2012 Mar; 10(1):21-5. PMID: 22130293.
    View in: PubMed
  138. D'Amico AV, Chen MH, de Castro M, Loffredo M, Lamb DS, Steigler A, Kantoff PW, Denham JW. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol. 2012 Feb; 13(2):189-95. PMID: 22112793.
    View in: PubMed
  139. Nguyen PL, Chen MH, Hoffman KE, Chen RC, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int. 2012 Jul; 110(2):201-5. PMID: 22085233.
    View in: PubMed
  140. D'Amico AV, Chen MH, Crook J, Armstrong JG, Malone S, Steigler A, Dunne M, Kantoff PW, Denham JW. Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. J Clin Oncol. 2011 Dec 10; 29(35):4682-7. PMID: 22042952.
    View in: PubMed
  141. Mitin T, Chen MH, Zhang Y, Moran BJ, Dosoretz DE, Katin MJ, Braccioforte MH, Salenius SA, D'Amico AV. Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy. J Urol. 2011 Dec; 186(6):2233-7. PMID: 22019035.
    View in: PubMed
  142. Kishan AU, Chen MH, Loffredo M, Kim D, Beard CJ, Hurwitz MD, Martin NE, Orio PF, Kantoff PW, D'Amico AV, Nguyen PL. Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):172-8. PMID: 24674120.
    View in: PubMed
  143. Kang J, Chen MH, Zhang Y, Moran BJ, Dosoretz DE, Katin MJ, Braccioforte MH, Salenius SA, D'Amico AV. Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):e463-7. PMID: 21944463.
    View in: PubMed
  144. D'Amico AV, Chen MH, Dosoretz D, Katin M, Salenius S, Ross R, Goldhaber SZ. Coronary artery revascularization and the risk of death in men with prostate cancer. J Urol. 2011 Sep; 186(3):898-902. PMID: 21788044.
    View in: PubMed
  145. D'Amico AV. Risk-based management of prostate cancer. N Engl J Med. 2011 Jul 14; 365(2):169-71. PMID: 21751910.
    View in: PubMed
  146. Mazzone E, Vasco G, Sormani MP, Torrente Y, Berardinelli A, Messina S, D'Amico A, Doglio L, Politano L, Cavallaro F, Frosini S, Bello L, Bonfiglio S, Zucchini E, De Sanctis R, Scutifero M, Bianco F, Rossi F, Motta MC, Sacco A, Donati MA, Mongini T, Pini A, Battini R, Pegoraro E, Pane M, Gasperini S, Previtali S, Napolitano S, Martinelli D, Bruno C, Vita G, Comi G, Bertini E, Mercuri E. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology. 2011 Jul 19; 77(3):250-6. PMID: 21734183.
    View in: PubMed
  147. Nguyen PL, Chen MH, Beckman JA, Beard CJ, Martin NE, Choueiri TK, Hu JC, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D'Amico AV, Ennis RD. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys. 2012 Mar 15; 82(4):1411-6. PMID: 21708431.
    View in: PubMed
  148. Park JJ, Chen MH, Loffredo M, D'Amico AV. Prostate-specific antigen velocity before and after elimination of factors that can confound the prostate-specific antigen level. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):1217-21. PMID: 21640512.
    View in: PubMed
  149. Talcott JA, Zietman AL, Kaplan ID, Clark JA, D'Amico AV. Does prostate brachytherapy that avoids the central zone prevent long-term urinary incontinence? Five-year results of a multi-institutional comparative cohort study. J Clin Oncol. 2011 May 20; 29(15_suppl):4665. PMID: 28023888.
    View in: PubMed
  150. Bardia A, Cowan JE, Carroll P, D'Amico AV, Carducci MA. Association of angiotensin II blockers with survival among men with prostate cancer: Results from CaPSURE. J Clin Oncol. 2011 May 20; 29(15_suppl):4538. PMID: 28023417.
    View in: PubMed
  151. Ennis KY, Chen M, Smith GC, D'Amico AV, Zhang Y, Harrison LB, Ennis RD. The impact of economic recession on the incidence and treatment of cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):6005. PMID: 28022012.
    View in: PubMed
  152. Arvold ND, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Bañez LL, Katin MJ, Braccioforte MH, D'Amico AV. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J Urol. 2011 Jul; 186(1):91-6. PMID: 21571341.
    View in: PubMed
  153. Winkfield KM, Chen MH, Dosoretz DE, Salenius SA, Katin M, Ross R, D'Amico AV. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e345-50. PMID: 21514066.
    View in: PubMed
  154. D'Amico AV. Future of treatment for low-risk prostate cancer: for all, for some, or for none? J Clin Oncol. 2011 May 20; 29(15):1940-3. PMID: 21464414.
    View in: PubMed
  155. Cotter SE, Chen MH, Moul JW, Lee WR, Koontz BF, Anscher MS, Robertson CN, Walther PJ, Polascik TJ, D'Amico AV. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011 Sep 01; 117(17):3925-32. PMID: 21437885.
    View in: PubMed
  156. Hattangadi JA, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice. Brachytherapy. 2011 Sep-Oct; 10(5):369-75. PMID: 21349778.
    View in: PubMed
  157. D'Amico AV, Chen MH, Sun L, Lee WR, Mouraviev V, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU Int. 2010 Dec; 106(11):1618-22. PMID: 20553253.
    View in: PubMed
  158. Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, Hu JC, Kuban DA, D'Amico AV. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol. 2011 Jan; 185(1):116-20. PMID: 21074194.
    View in: PubMed
  159. Crawford ED, Grubb R, Black A, Andriole GL, Chen MH, Izmirlian G, Berg CD, D'Amico AV. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011 Feb 01; 29(4):355-61. PMID: 21041707; PMCID: PMC3058283.
  160. Williams SB, D'Amico AV, Weinberg AC, Gu X, Lipsitz SR, Hu JC. Population-based determinants of radical prostatectomy surgical margin positivity. BJU Int. 2011 Jun; 107(11):1734-40. PMID: 20942827.
    View in: PubMed
  161. D'Amico AV. Is long-term androgen suppression right for everyone with locally advanced prostate cancer? Lancet Oncol. 2010 Nov; 11(11):1016-7. PMID: 20933467.
    View in: PubMed
  162. Choi WW, Gu X, Lipsitz SR, D'Amico AV, Williams SB, Hu JC. The effect of minimally invasive and open radical prostatectomy surgeon volume. Urol Oncol. 2012 Sep; 30(5):569-76. PMID: 20822929.
    View in: PubMed
  163. Katz MS, Carroll PR, Cowan JE, Chan JM, D'Amico AV. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int. 2010 Sep; 106(5):627-32. PMID: 20151961.
    View in: PubMed
  164. Nguyen PL, Chen MH, Goldhaber SZ, Martin NE, Beard CJ, Dosoretz DE, Katin MJ, Ross R, Salenius SA, D'Amico AV. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer. 2011 Jan 15; 117(2):406-13. PMID: 21108457.
    View in: PubMed
  165. Hu JC, Prasad SM, Gu X, Williams SB, Lipsitz SR, Nguyen PL, Choueiri TK, Choi WW, D'Amico AV. Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. Urology. 2011 Feb; 77(2):402-6. PMID: 20719365.
    View in: PubMed
  166. Ahove DA, Hoffman KE, Hu JC, Choueiri TK, D'Amico AV, Nguyen PL. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology. 2010 Nov; 76(5):1201-5. PMID: 20709376.
    View in: PubMed
  167. Nguyen PL, D'Amico AV. Deciding which patients to treat with salvage radiotherapy after prostatectomy. Oncology (Williston Park). 2010 Jul; 24(8):705, 711. PMID: 20718250.
    View in: PubMed
  168. Nanda A, D'Amico AV. Hormonal therapy and radiation for prostate cancer: is it safe? Expert Rev Anticancer Ther. 2010 Jul; 10(7):979-81. PMID: 20645684.
    View in: PubMed
  169. D'Amico AV, Goldhaber SZ. Ask the doctor. A year ago, I had an orchiectomy for prostate cancer; my PSA is now 0.74. Not long afterward, I had two cardiac stents implanted. I still have some angina and shortness of breath. I started Ranexa a couple of weeks ago, which helps my angina. Do you have any suggestions for my heart since I no longer make testosterone, which I understand helps protect men's hearts and arteries. Harv Heart Lett. 2010 Jul; 20(11):8. PMID: 20812421.
    View in: PubMed
  170. Nguyen PL, Chen MH, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Beard CJ, Dosoretz DE, Moran BJ, Katin MJ, Braccioforte MH, Ross R, Salenius SA, Kantoff PW, D'Amico AV. Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1318-22. PMID: 20605366.
    View in: PubMed
  171. Hoffman KE, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin MJ, Ross R, D'Amico AV. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer. 2010 Jun 01; 116(11):2590-5. PMID: 20310055.
    View in: PubMed
  172. D'Amico AV. Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer. J Clin Oncol. 2010 Jun 01; 28(16):2651-2. PMID: 20421530.
    View in: PubMed
  173. Choueiri TK, Chen MH, D'Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010 Apr 15; 116(8):1887-92. PMID: 20162710.
    View in: PubMed
  174. Cheung AK, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin M, Ross R, D'Amico AV. The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement. Brachytherapy. 2010 Apr-Jun; 9(2):145-50. PMID: 20346894.
    View in: PubMed
  175. Williams SB, Chen MH, D'Amico AV, Weinberg AC, Kacker R, Hirsch MS, Richie JP, Hu JC. Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology. 2010 Nov; 76(5):1097-101. PMID: 20303147.
    View in: PubMed
  176. Hoffman KE, Nguyen PL, Ng AK, D'Amico AV. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. J Urol. 2010 May; 183(5):1798-802. PMID: 20299039.
    View in: PubMed
  177. Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22. PMID: 20346051; PMCID: PMC3090683.
  178. Hayes JH, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin MJ, Ross R, Choueiri TK, D'Amico AV. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int. 2010 Oct; 106(7):979-85. PMID: 20230380.
    View in: PubMed
  179. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010 Mar-Apr; 60(2):70-98. PMID: 20200110.
    View in: PubMed
  180. Dosoretz AM, Chen MH, Salenius SA, Ross RH, Dosoretz DE, Katin MJ, Mantz C, Nakfoor BM, D'Amico AV. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy. Cancer. 2010 Feb 15; 116(4):837-42. PMID: 20052734.
    View in: PubMed
  181. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010 May-Jun; 60(3):194-201. PMID: 20124400; PMCID: PMC3049943.
  182. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010 Feb 16; 121(6):833-40. PMID: 20124128; PMCID: PMC3023973.
  183. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):162-200. PMID: 20141676.
    View in: PubMed
  184. Nguyen PL, Chen MH, Beard CJ, Suh WW, Choueiri TK, Efstathiou JA, Hoffman KE, Loffredo M, Kantoff PW, D'Amico AV. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer. 2010 Feb 01; 116(3):610-5. PMID: 19957321.
    View in: PubMed
  185. D'Amico AV, Braccioforte MH, Moran BJ, Chen MH. Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Jan-Mar; 24(1):85-9. PMID: 20556875.
    View in: PubMed
  186. Cormack RA, Sridhar S, Suh WW, D'Amico AV, Makrigiorgos GM. Biological in situ dose painting for image-guided radiation therapy using drug-loaded implantable devices. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):615-23. PMID: 19879699.
    View in: PubMed
  187. D'Amico AV, Braccioforte MH, Moran BJ, Chen MH. Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Aug 01; 77(5):1329-37. PMID: 19879061.
    View in: PubMed
  188. Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, McMahon E, Kantoff PW, D'Amico AV. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1046-52. PMID: 19864082.
    View in: PubMed
  189. Wo JY, Chen MH, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence. J Clin Oncol. 2009 Dec 10; 27(35):6000-5. PMID: 19858385.
    View in: PubMed
  190. Hu JC, Gu X, Lipsitz SR, Barry MJ, D'Amico AV, Weinberg AC, Keating NL. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009 Oct 14; 302(14):1557-64. PMID: 19826025.
    View in: PubMed
  191. Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):147-52. PMID: 19744800.
    View in: PubMed
  192. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009 Aug 26; 302(8):866-73. PMID: 19706860.
    View in: PubMed
  193. D'Amico AV, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, Chen MH. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol. 2009 Aug 20; 27(24):3923-8. PMID: 19597029.
    View in: PubMed
  194. Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D'Amico AV, Bennett C, Wei JT. The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology. 2010 Mar; 75(3):623-9. PMID: 19589569.
    View in: PubMed
  195. Mazzone ES, Messina S, Vasco G, Main M, Eagle M, D'Amico A, Doglio L, Politano L, Cavallaro F, Frosini S, Bello L, Magri F, Corlatti A, Zucchini E, Brancalion B, Rossi F, Ferretti M, Motta MG, Cecio MR, Berardinelli A, Alfieri P, Mongini T, Pini A, Astrea G, Battini R, Comi G, Pegoraro E, Morandi L, Pane M, Angelini C, Bruno C, Villanova M, Vita G, Donati MA, Bertini E, Mercuri E. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord. 2009 Jul; 19(7):458-61. PMID: 19553120.
    View in: PubMed
  196. Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1439-44. PMID: 19540066.
    View in: PubMed
  197. D'Amico AV, Chen MH. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer. J Clin Oncol. 2009 Aug 01; 27(22):3575-6. PMID: 19506151.
    View in: PubMed
  198. D'Amico AV, Braccioforte MH, Moran BJ, Chen M. Diabetes and the risk of death in men with favorable or high-risk prostate cancer following radiation therapy. J Clin Oncol. 2009 May 20; 27(15_suppl):5157. PMID: 27964473.
    View in: PubMed
  199. Winkfield KM, Chen M, Dosoretz DE, Salenius SA, Katin MJ, Ross R, D'Amico AV. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. J Clin Oncol. 2009 May 20; 27(15_suppl):5068. PMID: 27964249.
    View in: PubMed
  200. Nanda A, Chen M, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with radiation therapy. J Clin Oncol. 2009 May 20; 27(15_suppl):9543. PMID: 27963605.
    View in: PubMed
  201. Hayes JH, Chen M, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Short-course androgen suppression therapy prior to brachytherapy for favorable-risk prostate cancer and the risk of all-cause mortality in men with or without preexisting cardiovascular disease. J Clin Oncol. 2009 May 20; 27(15_suppl):5066. PMID: 27964251.
    View in: PubMed
  202. Nguyen PL, Chen MH, Beard CJ, Loffredo M, Renshaw AA, Suh WW, Kantoff PW, D'Amico AV. Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa). J Clin Oncol. 2009 May 20; 27(15_suppl):5129. PMID: 27964400.
    View in: PubMed
  203. Hoffman KE, D'Amico AV. Prostate cancer screening practice among men age 75 and older: Results from a national survey. J Clin Oncol. 2009 May 20; 27(15_suppl):e16034. PMID: 27962959.
    View in: PubMed
  204. Nguyen PL, Chen RC, Clark JA, Cormack RA, Loffredo M, McMahon E, Nguyen AU, Suh WW, Tempany CM, D'Amico AV. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy. 2009 Oct-Dec; 8(4):345-52. PMID: 19428311; PMCID: PMC4084795.
  205. D'Amico AV, Stanford J. Probiotic use and clindamycin-induced hypercholesterolemia. J Altern Complement Med. 2009 May; 15(5):470-1. PMID: 19450164.
    View in: PubMed
  206. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys. 2009 Sep 01; 75(1):10-5. PMID: 19395184.
    View in: PubMed
  207. Nguyen PL, Chen MH, Renshaw AA, Loffredo M, Kantoff PW, D'Amico AV. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):337-41. PMID: 19395186.
    View in: PubMed
  208. Nguyen PL, Chen MH, Hoffman KE, Katz MS, D'Amico AV. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys. 2009 May 01; 74(1):104-9. PMID: 19286330.
    View in: PubMed
  209. Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009 Mar 01; 115(5):981-7. PMID: 19152438; PMCID: PMC2931827.
  210. Nanda A, Chen MH, D'Amico AV. Mathematical rigor is necessary, but for men with prostate cancer, clinical relevance is the priority. J Clin Oncol. 2009 Apr 01; 27(10):1728-9; author reply 1729. PMID: 19237624.
    View in: PubMed
  211. Chen RC, Sadetsky N, Chen MH, Carroll PR, D'Amico AV. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy. Int J Radiat Oncol Biol Phys. 2009 Sep 01; 75(1):36-9. PMID: 19233568.
    View in: PubMed
  212. Nanda A, Chen MH, Renshaw AA, D'Amico AV. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys. 2009 Aug 01; 74(5):1419-23. PMID: 19131185.
    View in: PubMed
  213. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer. 2008 Dec 15; 113(12):3290-7. PMID: 18980297.
    View in: PubMed
  214. Nguyen PL, Chen MH, Catalona WJ, Alexander BM, Roehl KA, Loeb S, D'Amico AV. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer. 2008 Dec 01; 113(11):3146-52. PMID: 18932254.
    View in: PubMed
  215. Chen AB, D'Amico AV, Neville BA, Steyerberg EW, Earle CC. Provider case volume and outcomes following prostate brachytherapy. J Urol. 2009 Jan; 181(1):113-8; discussion 118. PMID: 19012905.
    View in: PubMed
  216. Sommers BD, Beard CJ, D'Amico AV, Kaplan I, Richie JP, Zeckhauser RJ. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer. 2008 Oct 15; 113(8):2058-67. PMID: 18704993.
    View in: PubMed
  217. Nanda A, D'Amico AV. Combined radiation and hormonal therapy or dose escalation for men with unfavourable-risk prostate cancer: an evidence-based approach using a synthesis of randomized clinical trials. BJU Int. 2008 Nov; 102(10):1366-8. PMID: 18778343.
    View in: PubMed
  218. Hoffman KE, Chen MH, Punglia RS, Beard CJ, D'Amico AV. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol. 2008 Aug 20; 26(24):3937-42. PMID: 18711182; PMCID: PMC2867767.
  219. Martin NE, Chen MH, Catalona WJ, Loeb S, Roehl KA, D'Amico AV. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis. Cancer. 2008 Aug 15; 113(4):717-22. PMID: 18615505.
    View in: PubMed
  220. Nguyen PL, Chen MH, Catalona WJ, Moul JW, Sun L, D'Amico AV. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys. 2009 Mar 01; 73(3):659-64. PMID: 18692327.
    View in: PubMed
  221. Loeb S, Sutherland DE, D'Amico AV, Roehl KA, Catalona WJ. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology. 2008 Nov; 72(5):1116-20; discussion 1120. PMID: 18571700.
    View in: PubMed
  222. D'Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol. 2008 Jun 20; 26(18):2979-83. PMID: 18565884.
    View in: PubMed
  223. De Filippis D, Russo A, D'Amico A, Esposito G, Pietropaolo C, Concetta P, Cinelli M, Russo G, Iuvone T. Cannabinoids reduce granuloma-associated angiogenesis in rats by controlling transcription and expression of mast cell protease-5. Br J Pharmacol. 2008 Aug; 154(8):1672-9. PMID: 18552882; PMCID: PMC2518473.
  224. Nguyen PL, Lei J, Mueller E, Signoretti S, D'Amico AV, Lin D, Pagano M, Weinstein MH, Loda M. The association between overexpression of skp2 and the risk of recurrence following prostatectomy. J Clin Oncol. 2008 May 20; 26(15_suppl):11052. PMID: 27947642.
    View in: PubMed
  225. Vira MA, Guzzo T, Heitjan DF, Tomaszewski JE, D'Amico A, Wein AJ, Malkowicz SB. Is the biopsy Gleason score important in predicting outcomes for patients after radical prostatectomy once the pathological Gleason score is known? BJU Int. 2008 May; 101(10):1232-6. PMID: 18419697.
    View in: PubMed
  226. D'Amico A, Bono R, Pennazza G, Santonico M, Mantini G, Bernabei M, Zarlenga M, Roscioni C, Martinelli E, Paolesse R, Di Natale C. Identification of melanoma with a gas sensor array. Skin Res Technol. 2008 May; 14(2):226-36. PMID: 18412567.
    View in: PubMed
  227. Nguyen PL, D'Amico AV. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol. 2008 Apr 20; 26(12):2055-6; author reply 2056-7. PMID: 18421061.
    View in: PubMed
  228. Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008 Jun; 179(6):2181-5; discussion 2185-6. PMID: 18423743; PMCID: PMC2667701.
  229. D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology. 2008 May; 71(5):933-7. PMID: 18291508.
    View in: PubMed
  230. D'Amico AV. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer. J Clin Oncol. 2008 Feb 20; 26(6):823-4. PMID: 18281649.
    View in: PubMed
  231. Sengupta S, Amling C, D'Amico AV, Blute ML. Prostate specific antigen kinetics in the management of prostate cancer. J Urol. 2008 Mar; 179(3):821-6. PMID: 18221963.
    View in: PubMed
  232. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008 Jan 23; 299(3):289-95. PMID: 18212313.
    View in: PubMed
  233. Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology. 2008 Jan; 71(1):136-40. PMID: 18242382.
    View in: PubMed
  234. D'Amico AV, Kantoff PW, Chen MH. Aspirin and hormone therapy for prostate cancer. N Engl J Med. 2007 Dec 27; 357(26):2737-8. PMID: 18160699.
    View in: PubMed
  235. Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR. Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSURE database. Urol Oncol. 2008 May-Jun; 26(3):271-5. PMID: 18452818.
    View in: PubMed
  236. D'Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):9-15. PMID: 18037582; PMCID: PMC2976647.
  237. Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer. 2007 Nov 15; 110(10):2210-7. PMID: 17893907.
    View in: PubMed
  238. Punglia RS, Cullen J, McLeod DG, Chen Y, D'Amico AV. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer. Cancer. 2007 Nov 01; 110(9):1973-8. PMID: 17886252.
    View in: PubMed
  239. Albert M, Song JS, Schultz D, Cormack RA, Tempany CM, Haker S, Devlin PM, Beard C, Hurwitz MD, Suh WW, Jolesz F, D'Amico AV. Defining the rectal dose constraint for permanent radioactive seed implantation of the prostate. Urol Oncol. 2008 Mar-Apr; 26(2):147-52. PMID: 18312933.
    View in: PubMed
  240. D'Amico AV, Renshaw AA, Loffredo B, Chen MH. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer. 2007 Oct 15; 110(8):1723-8. PMID: 17828774.
    View in: PubMed
  241. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007 Oct 17; 99(20):1516-24. PMID: 17925537.
    View in: PubMed
  242. Patel AA, Chen MH, Renshaw AA, D'Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA. 2007 Oct 03; 298(13):1533-8. PMID: 17911498.
    View in: PubMed
  243. Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007 Oct 01; 110(7):1417-28. PMID: 17694553.
    View in: PubMed
  244. Nguyen PL, Chen MH, D'Amico AV, Tempany CM, Steele GS, Albert M, Cormack RA, Carr-Locke DL, Bleday R, Suh WW. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer. 2007 Oct 01; 110(7):1485-92. PMID: 17701957.
    View in: PubMed
  245. Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Walsh PC. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Aug; 5(7):650-83. PMID: 17692170.
    View in: PubMed
  246. Nguyen PL, Chen MH, Renshaw AA, Sussman B, D'Amico AV. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality. Urology. 2007 Aug; 70(2):288-93. PMID: 17826491.
    View in: PubMed
  247. Alexander BM, Chen MH, Carroll P, D'Amico AV. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response. Urology. 2007 Aug; 70(2):320-3. PMID: 17826497.
    View in: PubMed
  248. Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. J Urol. 2007 Sep; 178(3 Pt 2):S5-8; quiz S4. PMID: 17644118.
    View in: PubMed
  249. Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database. Urology. 2007 Jul; 70(1):106-10. PMID: 17656218.
    View in: PubMed
  250. D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer. 2007 Jul 01; 110(1):56-61. PMID: 17530618.
    View in: PubMed
  251. Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus S, Liebert M, Moul JW, Tangen C, Thrasher JB, Thompson I. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007 Aug; 178(2):597-601. PMID: 17570435.
    View in: PubMed
  252. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007 Jun 10; 25(17):2420-5. PMID: 17557956.
    View in: PubMed
  253. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun; 177(6):2106-31. PMID: 17509297.
    View in: PubMed
  254. Lee AK, D'Amico AV. Using prostate-specific antigen doubling time in clinical practice. BJU Int. 2007 Aug; 100(2):243-4. PMID: 17511769.
    View in: PubMed
  255. D'Amico AV, Denham JW, Bolla M, Collette L, Lamb DS, Tai KH, Steigler A, Chen MH. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer. 2007 May 15; 109(10):2004-10. PMID: 17397033.
    View in: PubMed
  256. Efstathiou JA, Chen MH, Renshaw AA, Loffredo MJ, D'Amico AV. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer. 2007 Apr 15; 109(8):1493-8. PMID: 17340594.
    View in: PubMed
  257. D'Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer. 2007 Apr 01; 109(7):1290-5. PMID: 17315162.
    View in: PubMed
  258. Krejcarek SC, Chen MH, Renshaw AA, Loffredo M, Sussman B, D'Amico AV. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer. Urology. 2007 Mar; 69(3):515-9. PMID: 17382156.
    View in: PubMed
  259. Balboni TA, Chen MH, Harris JR, Recht A, Stevenson MA, D'Amico AV. Academic career selection and retention in radiation oncology: the Joint Center for Radiation Therapy experience. Int J Radiat Oncol Biol Phys. 2007 May 01; 68(1):183-6. PMID: 17276610.
    View in: PubMed
  260. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007 Feb; 177(2):540-5. PMID: 17222629.
    View in: PubMed
  261. Manganotti P, Zaina F, Vedovi E, Pistoia L, Rubilotta E, D'Amico A, Falso M. Repetitive magnetic stimulation of the sacral roots for the treatment of stress incontinence: a brief report. Eura Medicophys. 2007 Sep; 43(3):339-44. PMID: 17259914.
    View in: PubMed
  262. D'Amico AV. Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer. J Clin Oncol. 2007 Jan 01; 25(1):8-9. PMID: 17194901.
    View in: PubMed
  263. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol. 2007 Jan; 8(1):21-5. PMID: 17196507.
    View in: PubMed
  264. D'Amico A. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy. BJU Int. 2007 Jan; 99 Suppl 1:13-6; discussion 17-8. PMID: 17229162.
    View in: PubMed
  265. D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol. 2006 Dec; 176(6 Pt 2):S11-5. PMID: 17084157.
    View in: PubMed
  266. Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer. 2006 Dec 01; 107(11):2597-603. PMID: 17039498.
    View in: PubMed
  267. Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol. 2006 Nov 20; 24(33):5298-304. PMID: 17114664.
    View in: PubMed
  268. D'Amico AV, Barry MJ. Prostate cancer prevention and finasteride. J Urol. 2006 Nov; 176(5):2010-2; discussion 2012-3. PMID: 17070238.
    View in: PubMed
  269. Petit JH, Chen MH, Loffredo M, Sussman B, Renshaw AA, D'Amico AV. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. Cancer. 2006 Nov 01; 107(9):2180-5. PMID: 17009323.
    View in: PubMed
  270. Court LE, D'Amico AV, Kadam D, Cormack R. Motion and shape change when using an endorectal balloon during prostate radiation therapy. Radiother Oncol. 2006 Nov; 81(2):184-9. PMID: 17069915.
    View in: PubMed
  271. D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol. 2006 Sep 01; 24(25):4190-5. PMID: 16943536.
    View in: PubMed
  272. Rodrigues NA, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer. 2006 Aug 01; 107(3):514-20. PMID: 16795068.
    View in: PubMed
  273. Hurwitz MD, Schultz D, Richie JP, Wein AJ, Whittington R, Malkowicz SB, D'Amico AV. Radical prostatectomy for high-grade prostate cancer. Urology. 2006 Aug; 68(2):367-70. PMID: 16904454.
    View in: PubMed
  274. Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006 Aug; 68(2):342-7. PMID: 16904449.
    View in: PubMed
  275. D'Amico A, Gabbani M, Dall'oglio S, Cristofori L, Turazzi S, Sanzone E, Maluta S. Protracted administration of low doses of temozolomide (TMZ) in the treatment of relapse glioblastoma (GBM) enhances the antitumor activity of this agent. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1572. PMID: 27952533.
    View in: PubMed
  276. D'Amico AV, Cullen J, Chen Y, McLeod DG. Prostate-specific antigen velocity and the odds of detecting gleason 8 to 10 prostate cancer at biopsy. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4567. PMID: 27952018.
    View in: PubMed
  277. Chen AB, D'Amico AV, Neville BA, Earle CC. Predictors of complications following prostate brachytherapy. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6021. PMID: 27954580.
    View in: PubMed
  278. Tsai HK, Chen M, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-specific survival following radical prostatectomy or radiation therapy and short course hormonal therapy in men with localized, unfavorable-risk prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4572. PMID: 27952006.
    View in: PubMed
  279. MacDonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Bakst AW, Carroll PR. Predicting men at high risk for PSA failure after salvage radiotherapy for rising PSA following prostatectomy. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4570. PMID: 27952004.
    View in: PubMed
  280. Beard C, Schultz D, Loffredo M, Cote K, Renshaw AA, Hurwitz MD, D'Amico AV. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Oct 01; 66(2):403-7. PMID: 16765530.
    View in: PubMed
  281. Small EJ, Halabi S, Kantoff P, D'Amico A, Stadler W, Kelley WK, Mohler J, Bajorin D, Vogelzang NJ. Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3596s-600s. PMID: 16740791.
    View in: PubMed
  282. D'Amico AV, Kantoff P, Loffredo M, Renshaw AA, Loffredo B, Chen MH. Predictors of mortality after prostate-specific antigen failure. Int J Radiat Oncol Biol Phys. 2006 Jul 01; 65(3):656-60. PMID: 16682147.
    View in: PubMed
  283. D'Amico AV, Manola J, McMahon E, Loffredo M, Lopes L, Ching J, Albert M, Hurwitz M, Suh WW, Vivenzio TA, Beard C. A prospective evaluation of rectal bleeding after dose-escalated three-dimensional conformal radiation therapy using an intrarectal balloon for prostate gland localization and immobilization. Urology. 2006 Apr; 67(4):780-4. PMID: 16584760.
    View in: PubMed
  284. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level. Cancer. 2006 Apr 01; 106(7):1507-13. PMID: 16518812.
    View in: PubMed
  285. Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol. 2006 Mar; 175(3 Pt 1):907-12. PMID: 16469577.
    View in: PubMed
  286. Guzzo TJ, Vira M, Wang Y, Tomaszewski J, D'amico A, Wein AJ, Malkowicz SB. Preoperative parameters, including percent positive biopsy, in predicting seminal vesicle involvement in patients with prostate cancer. J Urol. 2006 Feb; 175(2):518-21; discussion 521-2. PMID: 16406985.
    View in: PubMed
  287. Mercuri E, Messina S, Battini R, Berardinelli A, Boffi P, Bono R, Bruno C, Carboni N, Cini C, Colitto F, D'Amico A, Minetti C, Mirabella M, Mongini T, Morandi L, Dlamini N, Orcesi S, Pelliccioni M, Pane M, Pini A, Swan AV, Villanova M, Vita G, Main M, Muntoni F, Bertini E. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscul Disord. 2006 Feb; 16(2):93-8. PMID: 16427782.
    View in: PubMed
  288. Rozhansky F, Chen MH, Cox MC, Dahut W, Figg WD, D'Amico AV. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer. 2006 Jan 01; 106(1):63-7. PMID: 16333854.
    View in: PubMed
  289. Punglia RS, Kuntz KM, Catalona WJ, D'Amico A. Operating characteristics of prostate-specific antigen and verification bias. JAMA. 2005 Dec 07; 294(21):2698; author reply 2698-9. PMID: 16333002.
    View in: PubMed
  290. Barnes AS, Haker SJ, Mulkern RV, So M, D'Amico AV, Tempany CM. Magnetic resonance spectroscopy-guided transperineal prostate biopsy and brachytherapy for recurrent prostate cancer. Urology. 2005 Dec; 66(6):1319. PMID: 16360468.
    View in: PubMed
  291. Lee AK, D'Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol. 2005 Nov 10; 23(32):8192-7. PMID: 16278472.
    View in: PubMed
  292. Kadoch C, D'Amico AV, Matthews RH. When prostate brachytherapy fails: a case report and discussion. Oncologist. 2005 Nov-Dec; 10(10):799-805. PMID: 16314290.
    View in: PubMed
  293. Vira MA, Tomaszewski JE, Hwang WT, D'Amico AV, Whittington R, Vanarsdalen K, Wein AJ, Malkowicz SB. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients. Urology. 2005 Nov; 66(5):1015-9. PMID: 16286115.
    View in: PubMed
  294. Beard C, Chen MH, Cote K, Loffredo M, Renshaw A, Hurwitz M, D'Amico AV. Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer. Urology. 2005 Nov; 66(5):1020-3. PMID: 16286116.
    View in: PubMed
  295. Dvorak T, Chen MH, Renshaw AA, Loffredo M, Richie JP, D'Amico AV. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer. Urology. 2005 Nov; 66(5):1024-8. PMID: 16286117.
    View in: PubMed
  296. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005 Oct 01; 23(28):6992-8. PMID: 16192586.
    View in: PubMed
  297. Jones GB, Crasto CF, Mathews JE, Xie L, Mitchell MO, El-Shafey A, D'Amico AV, Bubley GJ. An image contrast agent selectively activated by prostate specific antigen. Bioorg Med Chem. 2006 Jan 15; 14(2):418-25. PMID: 16185875.
    View in: PubMed
  298. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005 Sep 20; 23(27):6556-60. PMID: 16170163.
    View in: PubMed
  299. McAleer SJ, Schultz D, Whittington R, Malkowicz SB, Renshaw A, Wein A, Richie JP, D'Amico AV. PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level. Urol Oncol. 2005 Sep-Oct; 23(5):311-7. PMID: 16144663.
    View in: PubMed
  300. D'Amico AV, Chen MH, Cox MC, Dahut W, Figg WD. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. Urology. 2005 Sep; 66(3):571-6. PMID: 16140080.
    View in: PubMed
  301. Guzzo TJ, Vira M, Hwang WT, D'amico A, Tomaszewski J, Whittington R, Wein AJ, Vanarsdalen K, Malkowicz SB. Impact of multiple biopsy cores on predicting final tumor volume in prostate cancer detected by a single microscopic focus of cancer on biopsy. Urology. 2005 Aug; 66(2):361-5. PMID: 16098364.
    View in: PubMed
  302. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol. 2005 Aug 01; 23(22):4975-9. PMID: 16051949.
    View in: PubMed
  303. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005 Jul 27; 294(4):440-7. PMID: 16046650.
    View in: PubMed
  304. Tsai HK, Manola J, Abner A, Talcott JA, D'Amico AV, Beard C. Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy. Urol Oncol. 2005 Jul-Aug; 23(4):230-7. PMID: 16018937.
    View in: PubMed
  305. Woel R, Beard C, Chen MH, Hurwitz M, Loffredo M, McMahon E, Ching J, Lopes L, D'Amico AV. Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):392-6. PMID: 15890580.
    View in: PubMed
  306. Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Evidence to support a decline in prostate cancer-specific mortality. J Clin Oncol. 2005 Jun; 23(16_suppl):4550. PMID: 27946374.
    View in: PubMed
  307. Stewart AJ, Scher H, Chen MH, McLeod D, Carroll P, Moul J, D'Amico A. The clinical significance of a PSA nadir > 0.2 to patients with a rising post-operative or post-radiation PSA treated with androgen deprivation. J Clin Oncol. 2005 Jun; 23(16_suppl):4547. PMID: 27946344.
    View in: PubMed
  308. D'Amico AV, Chen MH, Cox MC, Dahut W, Figg WD. Intermediate end point for survival for patients with hormone refractory metastatic prostate cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):4553. PMID: 27946378.
    View in: PubMed
  309. Talcott JA, Clark JA, Manola J, Zietman AL, Kaplan I, D'Amico AV, Coen J, Mitchell SP, Reilly CE. Using patient-reported outcomes to assess prostate brachytherapy technique. J Clin Oncol. 2005 Jun; 23(16_suppl):4697. PMID: 27946876.
    View in: PubMed
  310. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality following radical prostatectomy or radiation therapy. J Clin Oncol. 2005 Jun; 23(16_suppl):4548. PMID: 27946342.
    View in: PubMed
  311. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Determination of mean population values of the prostate-specific antigen test after correcting for verification bias. J Clin Oncol. 2005 Jun; 23(16_suppl):6031. PMID: 27945182.
    View in: PubMed
  312. Nguyen PL, Whittington R, Koo S, Schultz D, Cote KB, Loffredo M, McMahon E, Renshaw AA, Tomaszewski JE, D'Amico AV. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer. 2005 May 15; 103(10):2053-9. PMID: 15816048.
    View in: PubMed
  313. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol. 2005 May; 173(5):1572-6. PMID: 15821488.
    View in: PubMed
  314. Landis DM, Schultz D, Cormack R, Tempany C, Beard C, Hurwitz M, O'Leary M, Albert M, Valentine K, D'Amico AV. Acute urinary retention after magnetic resonance image-guided prostate brachytherapy with and without neoadjuvant external beam radiotherapy. Urology. 2005 Apr; 65(4):750-4. PMID: 15833521.
    View in: PubMed
  315. D'Amico AV. Screening for prostate carcinoma: prostate-specific antigen--friend or foe? Cancer. 2005 Mar 01; 103(5):881-3. PMID: 15637686.
    View in: PubMed
  316. Lin DD, Schultz D, Renshaw AA, Rubin MA, Richie JP, D'Amico AV. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era. Urology. 2005 Mar; 65(3):528-32. PMID: 15780370.
    View in: PubMed
  317. Song JS, Albert M, D'Amico AV, Cormack RA. A comparative study of rectal dose histograms in prostate brachytherapy: some analytic and numerical results. Med Phys. 2005 Feb; 32(2):437-47. PMID: 15789590.
    View in: PubMed
  318. D'Amico AV, Richie JP, editors. Urologic Oncology. 2004.
  319. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004 Nov; 172(5 Pt 2):S42-6; discussion S46-7. PMID: 15535442.
    View in: PubMed
  320. Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol. 2004 Nov; 172(5 Pt 2):S3-5. PMID: 15535434.
    View in: PubMed
  321. D'Amico AV, Renshaw AA, Cote K, Hurwitz M, Beard C, Loffredo M, Chen MH. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol. 2004 Sep 15; 22(18):3726-32. PMID: 15365069.
    View in: PubMed
  322. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004 Aug 18; 292(7):821-7. PMID: 15315996.
    View in: PubMed
  323. Nguyen PL, Whittington R, Koo S, Schultz D, Cote KB, Loffredo M, McMahon E, Renshaw AA, Tomaszewski JE, D'Amico AV. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4503. PMID: 28016012.
    View in: PubMed
  324. D'Amico AV, Halabi S, Vogelzang NJ, Small EJ. A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4506. PMID: 28016017.
    View in: PubMed
  325. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004 Jul 08; 351(2):125-35. PMID: 15247353.
    View in: PubMed
  326. Nguyen PL, Schultz D, Renshaw AA, Vollmer RT, Welch WR, Cote K, D'Amico AV. The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate. Urol Oncol. 2004 Jul-Aug; 22(4):295-9. PMID: 15283886.
    View in: PubMed
  327. Jones GB, Xie L, El-Shafey A, Crasto CF, Bubley GJ, D'Amico AV. Image contrast agents activated by prostate specific antigen (PSA). Bioorg Med Chem Lett. 2004 Jun 21; 14(12):3081-4. PMID: 15149649.
    View in: PubMed
  328. Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, Soule HR, D'Amico AV. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res. 2004 Jun 01; 10(11):3927-33. PMID: 15173102.
    View in: PubMed
  329. Nguyen PL, Whittington R, Koo S, Schultz D, Cote KB, Loffredo M, Tempany CM, Titelbaum DS, Schnall MD, Renshaw AA, Tomaszewski JE, D'Amico AV. Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):400-5. PMID: 15145155.
    View in: PubMed
  330. Seo PH, D'Amico AV, Clark JA, Kaplan I, Manola JB, Mitchell SP, Talcott JA. Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms: a potential early indicator for technology assessment? Clin Prostate Cancer. 2004 Jun; 3(1):38-42. PMID: 15279689.
    View in: PubMed
  331. Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res. 2004 Jun 01; 10(11):3881-4. PMID: 15173097.
    View in: PubMed
  332. Sanghani MV, Ching J, Schultz D, Cormack R, Loffredo M, McMahon E, Beard C, D'Amico AV. Impact on rectal dose from the use of a prostate immobilization and rectal localization device for patients receiving dose escalated 3D conformal radiation therapy. Urol Oncol. 2004 May-Jun; 22(3):165-8. PMID: 15271308.
    View in: PubMed
  333. D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst. 2004 Apr 07; 96(7):509-15. PMID: 15069112.
    View in: PubMed
  334. D'Amico AV. Comments on "Patient selection for prostate brachytherapy: more myth than fact" by Merrick GS, Wallner KE, Butler WM. Oncology. 2004; 18.
  335. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 01; 22(3):537-56. PMID: 14752077.
    View in: PubMed
  336. Bloom KD, Richie JP, Schultz D, Renshaw A, Saegaert T, D'amico AV. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. Urology. 2004 Feb; 63(2):333-6. PMID: 14972484.
    View in: PubMed
  337. Dickhaus CF, Burghart C, Tempany C, D'Amico A, Haker S, Kikinis R, Woern H. Workflow modeling and analysis of computer guided prostate brachytherapy under MR imaging control. Stud Health Technol Inform. 2004; 98:72-4. PMID: 15544246.
    View in: PubMed
  338. Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M, D'Amico AV. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys. 2004 Jan 01; 58(1):19-24. PMID: 14697416.
    View in: PubMed
  339. D'amico AV, Tempany CM, Schultz D, Cormack RA, Hurwitz M, Beard C, Albert M, Kooy H, Jolesz F, Richie JP. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology. 2003 Dec; 62(6):1063-7. PMID: 14665356.
    View in: PubMed
  340. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PW. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol. 2003 Dec; 170(6 Pt 2):S3-5. PMID: 14610403.
    View in: PubMed
  341. Cooperberg MR, Small EJ, D'Amico A, Carroll PR. The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urol Nefrol. 2003 Dec; 55(4):219-38. PMID: 14765015.
    View in: PubMed
  342. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol. 2003 Dec; 170(6 Pt 2):S42-6; discussion S46-7. PMID: 14610409.
    View in: PubMed
  343. Talcott JA, Manola J, Clark JA, Kaplan I, Beard CJ, Mitchell SP, Chen RC, O'Leary MP, Kantoff PW, D'Amico AV. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003 Nov 01; 21(21):3979-86. PMID: 14581420.
    View in: PubMed
  344. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003 Sep 17; 95(18):1376-83. PMID: 13130113.
    View in: PubMed
  345. Albert M, Tempany CM, Schultz D, Chen MH, Cormack RA, Kumar S, Hurwitz MD, Beard C, Tuncali K, O'Leary M, Topulos GP, Valentine K, Lopes L, Kanan A, Kacher D, Rosato J, Kooy H, Jolesz F, Carr-Locke DL, Richie JP, D'Amico AV. Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer. 2003 Sep 01; 98(5):949-54. PMID: 12942561.
    View in: PubMed
  346. D'Amico AV, Harris JR, Loeffler JA, editors. Imaging in the Detection and Treatment of Cancer. 2003.
  347. Sanghani MV, Schultz D, Tempany CM, Titelbaum D, Renshaw AA, Loffredo M, Cote K, McMahon B, D'Amico AV. Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer. Urology. 2003 Sep; 62(3):487-91. PMID: 12946752.
    View in: PubMed
  348. Renshaw AA, Schultz D, Cote K, Loffredo M, Ziemba DE, D'Amico AV. Accurate Gleason grading of prostatic adenocarcinoma in prostate needle biopsies by general pathologists. Arch Pathol Lab Med. 2003 Aug; 127(8):1007-8. PMID: 12873176.
    View in: PubMed
  349. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003 Jul 24; 349(4):335-42. PMID: 12878740.
    View in: PubMed
  350. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003 Jun 01; 21(11):2163-72. PMID: 12775742.
    View in: PubMed
  351. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol. 2003 Apr; 169(4):1320-4. PMID: 12629352.
    View in: PubMed
  352. Lee AK, Doytchinova T, Chen MH, Renshaw AA, Weinstein M, Richie JP, D'Amico AV. Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core? Urol Oncol. 2003 Mar-Apr; 21(2):123-7. PMID: 12856640.
    View in: PubMed
  353. D'Amico AV. Therapeutic strategies for localized and locally advanced prostate cancer: combining androgen suppression with definitive local therapy. Rev Urol. 2003; 5 Suppl 6:S40-6. PMID: 16985976; PMCID: PMC1502370.
  354. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma. Cancer. 2003 Jan 01; 97(1):56-62. PMID: 12491505.
    View in: PubMed
  355. Cheng GC, Chen MH, Whittington R, Malkowicz SB, Schnall MD, Tomaszewski JE, D'Amico AV. Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA
    View in: PubMed
  356. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 2002 Dec 01; 20(23):4567-73. PMID: 12454114.
    View in: PubMed
  357. D'Amico AV, Toupless G, Lopes L, Valentine KJ, Cormack RA, Tempany CM, Kumar S, Marks PJ. Self-administration of untested medical therapy for treatment of prostate cancer can lead to clinically significant adverse events. Int J Radiat Oncol Biol Phys. 2002 Dec 01; 54(5):1311-3. PMID: 12459351.
    View in: PubMed
  358. D'Amico AV. How to compare results after surgery or radiation for localized prostate carcinoma. Cancer. 2002 Nov 15; 95(10):2041-3. PMID: 12412155.
    View in: PubMed
  359. Das P, Chen MH, Valentine K, Lopes L, Cormack RA, Renshaw AA, Tempany CM, Kumar S, D'Amico AV. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys. 2002 Nov 01; 54(3):698-702. PMID: 12377320.
    View in: PubMed
  360. D'Amico AV, Chen MH, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, Richie JP. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):436-41. PMID: 12243819.
    View in: PubMed
  361. Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology. 2002 Sep; 60(3):458-63. PMID: 12350484.
    View in: PubMed
  362. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):1-6. PMID: 12231036.
    View in: PubMed
  363. D'Amico AV. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):32-7; discussion 37-8. PMID: 12231043.
    View in: PubMed
  364. Yoon JH, Chen MH, Renshaw AA, Richie JP, D'Amico AV. Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer. Urology. 2002 Sep; 60(3):454-7. PMID: 12350483.
    View in: PubMed
  365. Hurwitz MD, Schnieder L, Manola J, Beard CJ, Kaplan ID, D'Amico AV. Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1106-10. PMID: 12128108.
    View in: PubMed
  366. D'Amico AV. Predicting prostate-specific antigen recurrence established: now, who will survive? J Clin Oncol. 2002 Aug 01; 20(15):3188-90. PMID: 12149288.
    View in: PubMed
  367. Hirose M, Bharatha A, Hata N, Zou KH, Warfield SK, Cormack RA, D'Amico A, Kikinis R, Jolesz FA, Tempany CM. Quantitative MR imaging assessment of prostate gland deformation before and during MR imaging-guided brachytherapy. Acad Radiol. 2002 Aug; 9(8):906-12. PMID: 12186439.
    View in: PubMed
  368. D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002 Jul 15; 95(2):281-6. PMID: 12124827.
    View in: PubMed
  369. Lieberfarb ME, Schultz D, Whittington R, Malkowicz B, Tomaszewski JE, Weinstein M, Wein A, Richie JP, D'Amico AV. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int J Radiat Oncol Biol Phys. 2002 Jul 15; 53(4):898-903. PMID: 12095555.
    View in: PubMed
  370. D'Amico AV, Saegaert T, Chen MH, Renshaw AA, George D, Oh W, Kantoff PW. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer. 2002 Jul 15; 95(2):275-80. PMID: 12124826.
    View in: PubMed
  371. D'Amico AV, Keshaviah A, Manola J, Cote K, Loffredo M, Iskrzytzky O, Renshaw AA. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Jul 01; 53(3):581-7. PMID: 12062600.
    View in: PubMed
  372. Cross CK, Shultz D, Malkowicz SB, Huang WC, Whittington R, Tomaszewski JE, Renshaw AA, Richie JP, D'Amico AV. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol. 2002 Jun 15; 20(12):2863-8. PMID: 12065563.
    View in: PubMed
  373. D'Amico AV, Chen MH, Malkowicz SB, Whittington R, Renshaw AA, Tomaszewski JE, Samofalov Y, Wein A, Richie JP. Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less. J Urol. 2002 May; 167(5):2025-30; discussion 2030-1. PMID: 11956431.
    View in: PubMed
  374. Linson PW, Lee AK, Doytchinova T, Chen MH, Weinstein MH, Richie JP, D'Amico AV. Percentage of core lengths involved with prostate cancer: does it add to the percentage of positive prostate biopsies in predicting postoperative prostate-specific antigen outcome for men with intermediate-risk prostate cancer? Urology. 2002 May; 59(5):704-8. PMID: 11992844.
    View in: PubMed
  375. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002 Mar; 1(2):203-9. PMID: 12086878.
    View in: PubMed
  376. D'Amico AV. The benefits of MR-guided interstitial prostate brachytherapy. Contemporary Urology. 2002; 14:16-30.
  377. D'Amico AV, Richie JP. Combined Modality Staging for Predicting PSA Outcome Following Radical Prostatectomy for Clinically Localized Adenocarcinoma of the Prostate. 2002 AUA Update Series. 2002; 20:10-16.
  378. Hsiung P, Ko TH, Li XD, Fujimoto JG, Weinstein M, D'Amico AV, Richie JP. Intraoperative imaging using optical coherence tomography. Optics Letters. 2002.
  379. D'Amico AV, Crook J, Beard CJ, Hurwitz M, DeWeese T, Kaplan I. Radiotherapeutic Management of Adenocarcinoma of the Prostate. Campbell's Urology. 2002.
  380. Kantoff P, Carroll PR, D'Amico AV, editors. Prostate Cancer. 2001.
  381. Finazzi Agrò E, Micali S, Maccarrone M, D'Amico A, Vespasiani G, Pasqualetti P, Caltagirone C. Urinary N-acetyl-beta-D-glucosaminidase concentration in patients with spinal cord injury: relationship with urodynamic parameters. Urology. 2001 Dec; 58(6):870-4. PMID: 11744448.
    View in: PubMed
  382. Bharatha A, Hirose M, Hata N, Warfield SK, Ferrant M, Zou KH, Suarez-Santana E, Ruiz-Alzola J, D'Amico A, Cormack RA, Kikinis R, Jolesz FA, Tempany CM. Evaluation of three-dimensional finite element-based deformable registration of pre- and intraoperative prostate imaging. Med Phys. 2001 Dec; 28(12):2551-60. PMID: 11797960.
    View in: PubMed
  383. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, Rhude M, Rocha S, Wein A, Richie JP. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol. 2001 Dec; 166(6):2185-8. PMID: 11696732.
    View in: PubMed
  384. D'Amico AV, Manola J, Loffredo M, Lopes L, Nissen K, O'Farrell DA, Gordon L, Tempany CM, Cormack RA. A practical method to achieve prostate gland immobilization and target verification for daily treatment. Int J Radiat Oncol Biol Phys. 2001 Dec 01; 51(5):1431-6. PMID: 11728704.
    View in: PubMed
  385. Porcaro AB, Zecchini Antoniolli S, Novella G, Martignoni G, Bassetto MA, Poli A, Schiavone D, Tallarigo C, D'Amico A, Ficarra V, Curti P. [Histopathologic risk factors in patients with non-seminomatous germ tumors of the testis in clinical stage 1. Retrospective study of 75 patients]. Arch Ital Urol Androl. 2001 Dec; 73(4):177-80. PMID: 11822063.
    View in: PubMed
  386. D'Amico AV. Perineural invasion as a predictor of PSA outcome following local therapy for patients with clinically localized prostate cancer. Cancer J. 2001 Sep-Oct; 7(5):375-6. PMID: 11693895.
    View in: PubMed
  387. D'Amico AV, Whittington R, Malkowicz SB, Renshaw AA, Tomaszewski JE, Bentley C, Schultz D, Rocha S, Wein A, Richie JP. Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening. Urology. 2001 Sep; 58(3):406-10. PMID: 11549489.
    View in: PubMed
  388. Cheung R, Altschuler MD, D'Amico AV, Malkowicz SB, Wein AJ, Whittington R. Using the receiver operating characteristic curve to select pretreatment and pathologic predictors for early and late postprostatectomy PSA failure. Urology. 2001 Sep; 58(3):400-5. PMID: 11549488.
    View in: PubMed
  389. Kaplan I, D'Amico AV. Brachytherapy. 2001 AUA Update Series. 2001.
  390. D'Amico A. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology. 2001 Aug; 58(2 Suppl 1):78-82. PMID: 11502455.
    View in: PubMed
  391. D'Amico AV. Combined-modality staging for localized adenocarcinoma of the prostate. Oncology (Williston Park). 2001 Aug; 15(8):1049-59; discussion 1060-2, 1064-5, 1069-70,1073-5. PMID: 11548976.
    View in: PubMed
  392. Hata N, Jinzaki M, Kacher D, Cormak R, Gering D, Nabavi A, Silverman SG, D'Amico AV, Kikinis R, Jolesz FA, Tempany CM. MR imaging-guided prostate biopsy with surgical navigation software: device validation and feasibility. Radiology. 2001 Jul; 220(1):263-8. PMID: 11426008.
    View in: PubMed
  393. D'Amico AV. Combined modality staging for clinically localized adenocarcinoma of the prostate as the basis for patient selection for randomized trials of neoadjuvant chemotherapy. Urol Oncol. 2001 Jul; 6(4):171-172. PMID: 11418324.
    View in: PubMed
  394. D'Amico AV, Cormack RA, Tempany CM. MRI-guided diagnosis and treatment of prostate cancer. N Engl J Med. 2001 Mar 08; 344(10):776-7. PMID: 11236795.
    View in: PubMed
  395. Lee AK, Schultz D, Renshaw AA, Richie JP, D'Amico AV. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys. 2001 Mar 01; 49(3):673-7. PMID: 11172948.
    View in: PubMed
  396. D'Amico AV, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2001 Mar 01; 49(3):679-84. PMID: 11172949.
    View in: PubMed
  397. D'Amico A, Piacentini I, Righetti R, Curti P, Ficarra V. [Exogenous risk factors for parenchymal carcinoma of the kidney]. Arch Ital Urol Androl. 2001 Mar; 73(1):49-55. PMID: 11505815.
    View in: PubMed
  398. Cheung R, Altschuler MD, D'Amico AV, Malkowicz SB, Wein AJ, Whittington R. ROC optimization may improve risk stratification of prostate cancer patients. Urology. 2001 Feb; 57(2):286-90. PMID: 11182338.
    View in: PubMed
  399. D'Amico AV, Tempany CM, Cormack R. The Role of Endorectal Coil MRI in the Staging, Therapy, and Outcome Assessment of Clincally Localized Prostate Cancer. 2001.
  400. D'Amico AV. Radiotherapy of Prostate Cancer by Greco C, Zelefsky MJ [review]. NEJM. 2001; 344:1723.
  401. Ficarra V, Righetti R, Martignoni G, D'Amico A, Pilloni S, Rubilotta E, Malossini G, Mobilio G. Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urol Int. 2001; 67(2):130-4. PMID: 11490206.
    View in: PubMed
  402. D'Amico AV, Cormack RA. Prostate Immobilization Device for 3D Conformal Radiation Therapy Treatment Delivery. 2001.
  403. Porcaro AB, D'Amico A, Ficarra V, Balzarro M, Righetti R, Martignoni G, Cavalleri S, Malossini G. Nephrogenic adenoma of the urinary bladder: our experience and review of the literature. Urol Int. 2001; 66(3):152-5. PMID: 11316978.
    View in: PubMed
  404. D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol. 2001 Jan; 165(1):126-9. PMID: 11125380.
    View in: PubMed
  405. Ficarra V, Righetti R, D'Amico A, Rubilotta E, Novella G, Malossini G, Mobilio G. Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology. 2001; 61(1):10-5. PMID: 11474242.
    View in: PubMed
  406. Shipley WU, D'Amico AV, Zietman AL, Zietman A. Radiation oncology update. Urol Oncol. 2000 Dec 15; 6(1):29-30. PMID: 11113370.
    View in: PubMed
  407. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2000 Dec; 3(4):259-264. PMID: 12497074.
    View in: PubMed
  408. Cormack RA, Tempany CM, D'Amico AV. Optimizing target coverage by dosimetric feedback during prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000 Nov 01; 48(4):1245-9. PMID: 11072185.
    View in: PubMed
  409. D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score
    View in: PubMed
  410. Cormack RA, D'Amico AV, Hata N, Silverman S, Weinstein M, Tempany CM. Feasibility of transperineal prostate biopsy under interventional magnetic resonance guidance. Urology. 2000 Oct 01; 56(4):663-4. PMID: 11018628.
    View in: PubMed
  411. D'Amico A, Lusuardi L, Ficarra V, Beltrami P, Malossini G, Tallarigo C, Mobilio G. Experience in the surgical treatment of Fraley's syndrome. Eur Urol. 2000 Oct; 38(4):410-4. PMID: 11025378.
    View in: PubMed
  412. D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Hurwitz M, Kantoff PW, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol. 2000 Sep 15; 18(18):3240-6. PMID: 10986056.
    View in: PubMed
  413. D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000 Sep 13; 284(10):1280-3. PMID: 10979115.
    View in: PubMed
  414. Jones GB, Mitchell MO, Weinberg JS, D'Amico AV, Bubley GJ. Towards enzyme activated antiprostatic agents. Bioorg Med Chem Lett. 2000 Sep 04; 10(17):1987-9. PMID: 10987433.
    View in: PubMed
  415. D'Amico AV, Whittington R, Malkowicz B, Schnall M, Schultz D, Cote K, Tomaszewski JE, Wein A. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol. 2000 Sep; 164(3 Pt 1):759-63. PMID: 10953141.
    View in: PubMed
  416. D'Amico AV, Tempany CM, Cormack R, Hata N, Jinzaki M, Tuncali K, Weinstein M, Richie JP. Transperineal magnetic resonance image guided prostate biopsy. J Urol. 2000 Aug; 164(2):385-7. PMID: 10893591.
    View in: PubMed
  417. Olumi AF, Richie JP, Schultz DJ, D'Amico AV. Calculated volume of prostate cancer identifies patients with clinical stage T1C disease at high risk of biochemical recurrence after radical prostatectomy: a preliminary study. Urology. 2000 Aug 01; 56(2):273-7. PMID: 10925093.
    View in: PubMed
  418. Thomas MD, Cormack R, Tempany CM, Kumar S, Manola J, Schneider L, Hurwitz MD, D'Amico AV. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000 Jul 01; 47(4):905-8. PMID: 10863058.
    View in: PubMed
  419. Hurwitz MD, Cormack R, Tempany CM, Kumar S, D'Amico AV. Three-dimensional real-time magnetic resonance-guided interstitial prostate brachytherapy optimizes radiation dose distribution resulting in a favorable acute side effect profile in patients with clinically localized prostate cancer. Tech Urol. 2000 Jun; 6(2):89-94. PMID: 10798806.
    View in: PubMed
  420. D'Amico AV, Schultz D, Schneider L, Hurwitz M, Kantoff PW, Richie JP. Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors. J Urol. 2000 Jun; 163(6):1797-801. PMID: 10799185.
    View in: PubMed
  421. D'Amico A, Cormack R, Kumar S, Tempany CM. Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer. J Endourol. 2000 May; 14(4):367-70. PMID: 10910153.
    View in: PubMed
  422. D'Amico AV, Weinstein M, Li X, Richie JP, Fujimoto J. Optical coherence tomography as a method for identifying benign and malignant microscopic structures in the prostate gland. Urology. 2000 May; 55(5):783-7. PMID: 10792101.
    View in: PubMed
  423. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7. Cancer. 2000 May 01; 88(9):2110-5. PMID: 10813723.
    View in: PubMed
  424. D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, Tomaszewski JE, Wein A. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology. 2000 Apr; 55(4):572-7. PMID: 10736506.
    View in: PubMed
  425. Bernstein MR, Cangiano T, D'Amico A, Chittams J, Hardy C, Whittington RD, Tomaszewski JE, Schnall MD, Wein AJ, Malkowicz SB. Endorectal coil magnetic resonance imaging and clinicopathologic findings in T1c adenocarcinoma of the prostate. Urol Oncol. 2000; 5(3):104-107.
  426. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000 Mar; 18(6):1164-72. PMID: 10715284.
    View in: PubMed
  427. D'Amico AV, Moul J, Kattan M. Biochemical Outcome after Radical Prostatectomy or External Beam Radiation Therapy for Clinically Localized Prostste Cancer. Vogelzang, NJ, editor. The Comprehensive Textbook of Genitourinary Oncology. 2000.
  428. Kooy HM, Cormack RA, Mathiowitz G, Tempany C, D'Amico AV. A software system for interventional magnetic resonance image-guided prostate brachytherapy. Comput Aided Surg. 2000; 5(6):401-13. PMID: 11295853.
    View in: PubMed
  429. Ficarra V, Righetti R, D'Amico A, Pilloni S, Balzarro M, Schiavone D, Malossini G, Mobilio G. General state of health and psychological well-being in patients after surgery for urological malignant neoplasms. Urol Int. 2000; 65(3):130-4. PMID: 11054029.
    View in: PubMed
  430. Cormack RA, Kooy H, Tempany CM, D'Amico AV. A clinical method for real-time dosimetric guidance of transperineal 125I prostate implants using interventional magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2000 Jan 01; 46(1):207-14. PMID: 10656394.
    View in: PubMed
  431. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. Mol Urol. 2000; 4(3):171-5;discussion 177. PMID: 11062371.
    View in: PubMed
  432. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Renshaw AA, Tomaszewski JE, Richie JP, Wein A. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage. Int J Radiat Oncol Biol Phys. 1999 Dec 01; 45(5):1227-33. PMID: 10613317.
    View in: PubMed
  433. D'Amico AV, Debruyne F, Huland H, Richie JP. Innovative treatment for clinically localized adenocarcinoma of the prostate: the future role of molecular imaging. Prostate. 1999 Nov 01; 41(3):208-12. PMID: 10517880.
    View in: PubMed
  434. D'Amico AV, Vogelzang NJ. Prostate brachytherapy: increasing demand for the procedure despite the lack of standardized quality assurance and long term outcome data. Cancer. 1999 Nov 01; 86(9):1632-4. PMID: 10547533.
    View in: PubMed
  435. D'Amico AV, Renshaw AA, Schultz D, Rocha S, Richie JP. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy. Int J Radiat Oncol Biol Phys. 1999 Nov 01; 45(4):847-51. PMID: 10571188.
    View in: PubMed
  436. D'Amico AV, Renshaw AA, Arsenault L, Schultz D, Richie JP. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy. Int J Radiat Oncol Biol Phys. 1999 Nov 01; 45(4):841-6. PMID: 10571187.
    View in: PubMed
  437. Prosnitz RG, Schneider L, Manola J, Rocha S, Loffredo M, Lopes L, D'Amico AV. Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study. Int J Radiat Oncol Biol Phys. 1999 Oct 01; 45(3):563-6. PMID: 10524406.
    View in: PubMed
  438. Ficarra V, Mofferdin A, D'Amico A, Zanon G, Schiavone D, Malossini G, Mobilio G. [Comparison of the quality of life of patients treated by surgery or radiotherapy in epidermoid cancer of the penis]. Prog Urol. 1999 Sep; 9(4):715-20. PMID: 10555226.
    View in: PubMed
  439. Vargas SO, Jiroutek M, D'Amico AV, Renshaw AA. Distribution of carcinoma in radical prostatectomy specimens in the era of serum prostate-specific antigen testing. Implications for delivery of localized therapy. Am J Clin Pathol. 1999 Sep; 112(3):373-6. PMID: 10478143.
    View in: PubMed
  440. Ciotti R, Belotti G, Facchi E, Cantù A, D'Amico A, Gatti C. Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine. Ann Oncol. 1999 Aug; 10(8):997. PMID: 10509166.
    View in: PubMed
  441. D'Amico AV. Analysis of the clinical utility of the use of salvage brachytherapy in patients who have a rising PSA after definitive external beam radiation therapy. Urology. 1999 Aug; 54(2):201-3. PMID: 10443710.
    View in: PubMed
  442. D'Amico AV. Biochemical Outcome after External Beam Radiation Therapy or Interstitial Radiation Therapy for Clinically Localized Adenocarcinoma of the Prostate. 1999 AUA Update Series. 1999; 18:234-240.
  443. D'Amico AV, Hanks GE, editors. Radiotherapeutic Management of Prostate Adenocarcinoma. 1999.
  444. Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV. Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostate-specific antigen failure in radical prostatectomy specimens. Validation in a cohort of 434 patients. Am J Clin Pathol. 1999 May; 111(5):641-4. PMID: 10230354.
    View in: PubMed
  445. Vargas SO, Jiroutek M, Welch WR, Nucci MR, D'Amico AV, Renshaw AA. Perineural invasion in prostate needle biopsy specimens. Correlation with extraprostatic extension at resection. Am J Clin Pathol. 1999 Feb; 111(2):223-8. PMID: 9930144.
    View in: PubMed
  446. D'Amico AV, Davis A, Vargas SO, Renshaw AA, Jiroutek M, Richie JP. Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated? Int J Radiat Oncol Biol Phys. 1999 Feb 01; 43(3):587-90. PMID: 10078642.
    View in: PubMed
  447. D'Amico AV, Cormack R, Kumar S, Tempany C. Real time magnetic resonance image guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. Journal of Endourology. 1999.
  448. Ficarra V, D'Amico A, Cavalleri S, Zanon G, Mofferdin A, Schiavone D, Malossini G, Mobilio G. Surgical treatment of penile carcinoma: our experience from 1976 to 1997. Urol Int. 1999; 62(4):234-7. PMID: 10567891.
    View in: PubMed
  449. Kaplan I, Jiroutek M, Henry DL, Beard CJ, D'Amico AV . Postprostatectomy External Beam Irradiation. The Prostate Journal. 1999; 1(1):32-7.
  450. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999 Jan; 17(1):168-72. PMID: 10458230.
    View in: PubMed
  451. Linggood R, Govern F, Coleman CN, D'Amico AV. A blueprint for linking academic oncology and the community. J Health Polit Policy Law. 1998; 23(6):973-94.
  452. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Tomaszewski JE, Wein A. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol. 1998 Dec; 160(6 Pt 1):2096-101. PMID: 9817331.
    View in: PubMed
  453. D'Amico AV, Desjardin A, Chen MH, Paik S, Schultz D, Renshaw AA, Loughlin KR, Richie JP. Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate. Cancer. 1998 Nov 15; 83(10):2172-80. PMID: 9827722.
    View in: PubMed
  454. D'Amico AV, Cormack R, Tempany CM, Kumar S, Topulos G, Kooy HM, Coleman CN. Real-time magnetic resonance image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):507-15. PMID: 9806508.
    View in: PubMed
  455. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urology. 1998 Oct; 52(4):631-6. PMID: 9763083.
    View in: PubMed
  456. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16; 280(11):969-74. PMID: 9749478.
    View in: PubMed
  457. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Loughlin KR, Richie JP, Wein A. Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. J Clin Oncol. 1998 Sep; 16(9):3094-100. PMID: 9738580.
    View in: PubMed
  458. Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer. 1998 Aug 15; 83(4):748-52. PMID: 9708940.
    View in: PubMed
  459. D'Amico AV, Desjardin A, Chung A, Chen MH. Assessment of outcome prediction models for localized prostate cancer in patients managed with external beam radiation therapy. Semin Urol Oncol. 1998 Aug; 16(3):153-9. PMID: 9741420.
    View in: PubMed
  460. D'Amico AV, Desjardin A, Chung A, Chen MH, Schultz D, Whittington R, Malkowicz SB, Wein A, Tomaszewski JE, Renshaw AA, Loughlin K, Richie JP. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer. 1998 May 15; 82(10):1887-96. PMID: 9587121.
    View in: PubMed
  461. Beard CJ, Lamb C, Buswell L, Schneider L, Propert KJ, Gladstone D, D'Amico A, Kaplan I. Radiation-associated morbidity in patients undergoing small-field external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1998 May 01; 41(2):257-62. PMID: 9607338.
    View in: PubMed
  462. D'Amico AV. Prostate Cancer and combined Modality Staging: Defining a patient's risk for extracapsular extension. 1998 AUA Update Series. 1998.
  463. D'Amico AV, Schnall M, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology. 1998 Mar; 51(3):449-54. PMID: 9510351.
    View in: PubMed
  464. D'Amico AV, Chang E, Garnick M, Kantoff P, Jiroutek M, Tempany CM. Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy. Urology. 1998 Feb; 51(2):287-92. PMID: 9495713.
    View in: PubMed
  465. D'Amico AV, Whittington R, Kaplan I, Beard C, Schultz D, Malkowicz SB, Wein A, Tomaszewski JE, Coleman CN. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter. Cancer. 1998 Jan 15; 82(2):334-41. PMID: 9445191.
    View in: PubMed
  466. Grim J, D'Amico A, Frizelle S, Zhou J, Kratzke RA, Curiel DT. Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2415-23. PMID: 9815642.
    View in: PubMed
  467. D'Amico AV, Whittington R, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A. Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol. 1997 Oct; 158(4):1422-6. PMID: 9302135.
    View in: PubMed
  468. D'Amico AV, Whittington R, Kaplan I, Beard C, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A, Coleman CN. Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. Int J Radiat Oncol Biol Phys. 1997 Sep 01; 39(2):335-40. PMID: 9308936.
    View in: PubMed
  469. Werner-Wasik M, Whittington R, Malkowicz SB, Corn BW, Arger P, Reisinger S, Langlotz C, Alexander A, D'Amico AV, Hyslop T, Gomella L, Brownstein K, Wein AJ. Prostate imaging may not be necessary in nonpalpable carcinoma of the prostate. Urology. 1997 Sep; 50(3):385-9. PMID: 9301702.
    View in: PubMed
  470. D'Amico A, Messa C, Castagna A, Zito F, Galli L, Pepe G, Lazzarin A, Lucignani G, Fazio F. Diagnostic accuracy and predictive value of 201T1 SPET for the differential diagnosis of cerebral lesions in AIDS patients. Nucl Med Commun. 1997 Aug; 18(8):741-50. PMID: 9293505.
    View in: PubMed
  471. Renshaw AA, Chang H, D'Amico AV. Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. Am J Clin Pathol. 1997 Jun; 107(6):704-8. PMID: 9169669.
    View in: PubMed
  472. D'Amico AV. Re: Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? J Urol. 1997 Apr; 157(4):1371; author reply 1372. PMID: 9120954.
    View in: PubMed
  473. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial. J Clin Oncol. 1997 Apr; 15(4):1465-9. PMID: 9193341.
    View in: PubMed
  474. D'Amico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malkowicz SB, Wein A, Coleman CN. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int J Radiat Oncol Biol Phys. 1997 Mar 15; 37(5):1053-8. PMID: 9169812.
    View in: PubMed
  475. D'Amico AV, Chang H, Holupka E, Renshaw A, Desjarden A, Chen M, Loughlin KR, Richie JP. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology. 1997 Mar; 49(3):385-91. PMID: 9123703.
    View in: PubMed
  476. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology. 1997 Mar; 49(3A Suppl):23-30. PMID: 9123732.
    View in: PubMed
  477. D'Amico AV, Matelski H, O'Leary M, Sussman B. Prostate-specific antigen-producing cells in the bone marrow of a patient with early-stage prostate cancer. Urology. 1997 Feb; 49(2):279-82. PMID: 9037298.
    View in: PubMed
  478. Wicks I, McColl G, D'Amico A, Dougherty L, Tait B. Use of monoclonal antibodies to detect disease associated HLA-DRB1 alleles and the shared epitope in rheumatoid arthritis. Ann Rheum Dis. 1997 Feb; 56(2):135-9. PMID: 9068289; PMCID: PMC1752326.
  479. D'Amico, AV, Cormack RA, Tempany CA, Kooy H. Magnetic Resonance Image Guided Prostate Interstitial Radiation Therapy. 1997.
  480. D'Amico AV, Bubley G, Weinberg J, Jebartanam. Prostate Specific Antigen Pro-Drug for the Treatment of Prostate Cancer. 1997.
  481. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. Role of percent positive biopsies and endorectal coil MRI in predicting prognosis in intermediate-risk prostate cancer patients. Cancer J Sci Am. 1996 Nov-Dec; 2(6):343-50. PMID: 9166555.
    View in: PubMed
  482. D'Amico AV. The role of MR imaging in the selection of therapy for prostate cancer. Magn Reson Imaging Clin N Am. 1996 Aug; 4(3):471-9. PMID: 8873014.
    View in: PubMed
  483. D'Amico AV. The role of magnetic resonance imaging in the selection of therapy for prostate cancer. Tempany C, editor. Radiologic Clinics of North America on the Male Pelvis. 1996.
  484. D'Amico AV. What is the optimal patient selection for combined androgen ablative and radiation therapy? The role of combined modality staging. Hematol Oncol Clin North Am. 1996 Jun; 10(3):643-51. PMID: 8773502.
    View in: PubMed
  485. D'Amico AV. Adjuvant and Neoadjuvant therapy in the treatment of clincally organ confined prostate cancer. Hematology Oncology Clinics of North America on The Management of Prostate Cancer. 1996.
  486. D'Amico AV, Goldwein J, Womer R. Alveolar rhabdomyosarcoma of the lip in an infant. Med Pediatr Oncol. 1996 Jun; 26(6):409-13. PMID: 8614378.
    View in: PubMed
  487. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol. 1996 Jun; 14(6):1770-7. PMID: 8656245.
    View in: PubMed
  488. D'Amico AV, Propert KJ. Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys. 1996 May 01; 35(2):273-9. PMID: 8635933.
    View in: PubMed
  489. D'Amico AV, Whittington R, Malkowicz SB, Loughlin K, Schultz D, Schnall M, Tempany CM, Tomaszewski JE, Renshaw A, Wein A. An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy. Urology. 1996 Apr; 47(4):538-47. PMID: 8638365.
    View in: PubMed
  490. D'Amico AV, McGovern R, Church R, Tempany C. Staging. Kantoff PW, Loughlin K, Wishnow K, editors. The Physician's guide to Prostate Cancer. 1996.
  491. D'Amico AV, Coleman CN. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. J Clin Oncol. 1996 Jan; 14(1):304-15. PMID: 8558212.
    View in: PubMed
  492. D'Amico AV, Kaplan I. Select transition zone prostate cancers may be radiocurable despite markedly elevated prostate-specific antigen levels. Radiother Oncol. 1996 Jan; 38(1):73-6. PMID: 8850429.
    View in: PubMed
  493. Wishnow K, D'Amico AV, Clinton S. Alternative Treatments. Kantoff PW, Loughlin K, Wishnow K, editors. The Physician's guide to Prostate Cancer. 1996.
  494. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol. 1995 Jul; 154(1):131-8. PMID: 7539857.
    View in: PubMed
  495. D'Amico AV, Whittington R, Malkowicz SB, Schultz D. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1995 May 15; 32(2):473-7. PMID: 7538502.
    View in: PubMed
  496. D'Amico AV, Whittington R, Schnall M, Malkowicz SB, Tomaszewski JE, Schultz D, Wein A. The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer. Cancer. 1995 May 01; 75(9):2368-72. PMID: 7536124.
    View in: PubMed
  497. D'Amico A, Cavalleri S, Rahmati M, Isgro A, Porcaro AB, Malossini G. A case of testicular metastasis from carcinoma of the prostate. Int Urol Nephrol. 1995; 27(5):593-6. PMID: 8775044.
    View in: PubMed
  498. Kao GD, Malkowicz SB, Whittington R, D'Amico AV, Wein AJ. Locally advanced renal cell carcinoma: low complication rate and efficacy of postnephrectomy radiation therapy planned with CT. Radiology. 1994 Dec; 193(3):725-30. PMID: 7972814.
    View in: PubMed
  499. D'Amico AV, McKenna WG. Apoptosis and a re-investigation of the biologic basis for cancer therapy. Radiother Oncol. 1994 Oct; 33(1):3-10. PMID: 7878207.
    View in: PubMed
  500. D'Amico AV, Whittington R, Malkowicz SB, Schnall M, Tomaszewski J, Schultz D, Kao G, VanArsdalen K, Wein A. A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 1994 Sep 30; 30(2):293-302. PMID: 7928457.
    View in: PubMed
  501. D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer. 1993 Nov 01; 72(9):2638-43. PMID: 7691393.
    View in: PubMed
  502. D'Amico A, Altschuler M, Whittington R, Kao G, Malkowicz SB, Wein A. The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer. Clin Perform Qual Health Care. 1993 Oct-Dec; 1(4):219-22. PMID: 10135639.
    View in: PubMed
  503. Hanks GE, D'Amico A, Epstein BE, Schultheiss TE. Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys. 1993 Sep 01; 27(1):125-7. PMID: 7690014.
    View in: PubMed
  504. Curti P, Malossini G, Piubello G, Comunale L, Bianchi G, Tallarigo C, Baldassarre R, Schiavone D, Cavalleri S, D'Amico A, et al. [The effects of unilateral spermatic cord torsion on fertility. A review of the literature and evaluation of the authors' own cases]. Chir Ital. 1992 Sep-Dec; 44(5-6):273-88. PMID: 1344150.
    View in: PubMed
  505. D'Amico A, Novella G, Monaco C, Motta L, Malossini G, Comunale L. [Transitory postoperative anuria after transvesical prostatic adenomectomy: review of the literature, description of new clinical cases and physiopathological considerations]. Chir Ital. 1992 Feb-Apr; 44(1-2):41-56. PMID: 1382878.
    View in: PubMed
  506. Bianchi G, Cavalleri S, D'Amico A, Tallarigo C, Malossini G, Beltrami P. [Treatment of renal cysts by percutaneous drainage and alcoholization. Our experience]. J Urol (Paris). 1990; 96(4):185-8. PMID: 2212715.
    View in: PubMed
  507. Cusimano F, Cocita VC, D'Amico A. Sensorineural hearing loss in chronic otitis media. J Laryngol Otol. 1989 Feb; 103(2):158-63. PMID: 2926260.
    View in: PubMed
  508. D'Amico AV, Nelson AC, Babayan RK. Thrombin: implications for intratumor therapy against metastasis. J Cancer Res Clin Oncol. 1988; 114(2):129-32. PMID: 3350846.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
D'Amico's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_